Modified filamentous fungal host cells

Abstract

The present invention relates to mutant filamentous fungal host cells that produce a secreted polypeptide of interest, wherein a putative native steroid dehydrogenase is modified, truncated, partially or completely inactivated, present at reduced levels, or eliminated compared to the non-mutated parent cell, and wherein the putative native steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT, as well as methods of producing a secreted polypeptide of interest in said cells and methods of producing said cells.

Description

[Technical field]

[0001] Reference to sequence listing This application contains a sequence listing in computer readable format, which is incorporated herein by reference.

[0002] The present invention relates to modified filamentous fungal cells and methods for producing such cells and methods for producing secreted polypeptides of interest therein. [Background technology]

[0003] Filamentous fungal host cells are widely used for the industrial production of a wide variety of polypeptides of interest. Intensive research efforts are directed to improving the production of polypeptides of interest in filamentous fungal host cells, in particular improving the productivity and / or yield. Summary of the Invention [Means for solving the problem]

[0004] The present inventors have found that modifying the genes encoding predicted putative steroid dehydrogenases in the enzyme-producing host cells results in improved productivity and / or yield of the enzyme.

[0005] Thus, in a first aspect, the present invention is directed to a mutant filamentous fungal host cell producing a secreted polypeptide of interest, wherein a putative native steroid dehydrogenase is modified, truncated, partially or completely inactivated, present at reduced levels or eliminated compared to a non-mutated parent cell, and wherein said putative native steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; preferably at least two of the conserved motifs; more preferably at least three or four of the conserved motifs; and most preferably comprises all five of the conserved motifs.

[0006] The modification, truncation, inactivation, reduction of the level or complete elimination of a putative native steroid dehydrogenase may be carried out by any suitable method known in the art, for example by reducing the expression of the coding gene by replacing the native promoter of said gene with a heterologous promoter, preferably a regulatable promoter. Another method for reducing the level of a putative steroid dehydrogenase may be to add a destabilizing domain, such as a ubiquitin domain, to the protein, thereby reducing the half-life of the protein. Furthermore, another method for inactivating, reducing the level or complete elimination of a putative native steroid dehydrogenase is to co-express or add one or more steroid dehydrogenase inhibitors. Examples of convenient methods for completely eliminating expression are gene deletion, gene replacement or gene interruption, for example by introducing a nonsense mutation into the coding sequence. Another method for modifying the coding sequence may be to introduce an internal deletion, either by deleting a part of the coding sequence or by mutating the coding sequence to alter intron processing. Further alternative methods for inactivating the putative steroid dehydrogenase could be to suppress its expression using RNA interference or siRNA or to insert a promoter and possibly terminator-less construct with the direction of transcription towards the end of the gene encoding the putative steroid dehydrogenase, resulting in steric hindrance of the transcription of the gene encoding the putative steroid dehydrogenase due to destabilization of the mRNA that could occur due to RNA polymerase collisions or formation of the mRNA molecule with a complementary sequence.

[0007] Thus, in a second aspect, the present invention provides a method for producing a mutant filamentous fungal host cell having an improved yield of a secreted polypeptide of interest compared to a non-mutated parent host cell, comprising, in no particular order: a) transforming a filamentous fungal host cell with a polynucleotide construct encoding a secreted polypeptide of interest; and b) mutating the host cell to modify, truncate, partially or completely inactivate, reduce the level of or eliminate a putative naturally occurring steroid dehydrogenase, wherein said putative naturally occurring steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; preferably, at least two of the conserved motifs; more preferably, at least three or four of the conserved motifs; and most preferably, all five of the conserved motifs.

[0008] A final aspect of the invention is a method for producing a secreted polypeptide of interest, comprising the steps of: a) culturing a mutant filamentous fungal host cell according to any preceding claim under conditions practical for the production of a secreted polypeptide; and optionally b) recovering the secreted polypeptide of interest; The present invention relates to a method comprising the steps of: [Brief description of the drawings]

[0009] [Figure 1] The plasmid map of pNJOC577 is shown. [Diagram 2] The plasmid map of pNJOC383 is shown. [Figure 3A] Figure 1 shows a multiple alignment of the four putative steroid dehydrogenases identified in SEQ ID NOs: 3, 6, 9 and 12. Identical residues are indicated by black boxes. Residues conserved in three of the four proteins are indicated by grey boxes. Proteins are aligned using the MUSCLE algorithm version 3.8.31 with default parameters (Edgar, RC (2004). Nucleic Acids Research, 32(5), 1792-1797). [Figure 3B] Same as explanation for Figure 3A. [Figure 4] The plasmid map of pNJOC569 is shown. [Diagram 5] Relative lysozyme productivity / yield (LSU(F) / ml) in strains NJOC587 (control) and NJOC618-81D (steroid dehydrogenase mutant) is shown. The LSU(F) / ml data in the control at the end of fermentation was used to normalize the data. In the figures, commas are used as decimal separators instead of the traditional decimal point. [Figure 6] The plasmid map of pTmmD-Tl_lipase is shown. [Figure 7] Relative lipase productivity / yield (LU(LXP) / ml) is shown for strains NJOC600-2A (control) and NJOC609-1A (steroid dehydrogenase mutant). The LU(LXP) / ml data for the control at the end of fermentation was used to normalize the data. In the figures, commas are used as decimal separators instead of the traditional decimal point. [Figure 8] The plasmid map of pSMai326 is shown. [Figure 9] Figure 1 shows the relative xanthanase productivity / yield in strains NJOC608-1B (control) and NJOC617-77C (steroid dehydrogenase mutant). The xanthanase yield in the control at the end of the fermentation was used to normalize the data. In the figures, commas are used as decimal separators instead of the traditional decimal point. [Figure 10] The plasmid map of pTmmD-Mf_lysozyme is shown. [Figure 11] Relative Mf lysozyme productivity / yield (LSU(A) / ml) in strains NJOC601-5A (control) and NJOC610-2B (steroid dehydrogenase mutant). The lysozyme yield in the control at the end of fermentation was used to normalize the data. In the figures, a comma is used as a decimal separator instead of the traditional decimal point. [Figure 12] The plasmid map of pIHAR473 is shown. [Figure 13] The plasmid map of pAT3631 is shown. [Figure 14] Relative phytase productivity / yield in strains AT3091 (control) and AT3944 (steroid dehydrogenase mutants) is shown. The phytase yield in the control at the end of fermentation was used to normalize the data. In the figures, commas are used as decimal separators instead of the traditional decimal point. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] definition cDNA: The term "cDNA" refers to a DNA molecule that can be prepared by reverse transcription from a mature spliced ​​mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial primary RNA transcript is a precursor of mRNA that is processed through a series of steps, including splicing, before emerging as the mature spliced ​​mRNA.

[0011] Coding sequence: The term "coding sequence" refers to a polynucleotide that directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon, such as ATG, GTG, or TTG, and ends with a stop codon, such as TAA, TAG, or TGA. The coding sequence may be genomic DNA, cDNA, synthetic DNA, or a combination thereof.

[0012] Control sequence: The term "control sequence" refers to a nucleic acid sequence necessary for expression of a polynucleotide encoding a mature polypeptide of the present invention. Each control sequence may be native (i.e., from the same gene) or foreign (i.e., from different genes) to the polynucleotide encoding the polypeptide, or native or foreign to each other. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator. At a minimum, control sequences include a promoter, and transcriptional and translational stop signals. Control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences with the coding region of the polynucleotide encoding the polypeptide.

[0013] Expression: The term "expression" includes any step involved in the production of a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0014] Expression Vector: The term "expression vector" includes a linear or circular DNA molecule that contains a polynucleotide that encodes a polypeptide and is operably linked to a control sequence that effects its expression.

[0015] Host cell: The term "host cell" refers to any cell type that is susceptible to transformation, transfection, transduction, etc., with a nucleic acid construct or expression vector comprising a polynucleotide of the invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.

[0016] Isolated: The term "isolated" refers to a substance in a form or environment that does not occur in nature. Non-limiting examples of isolated substances include: (1) any non-naturally occurring substance; (2) any substance, including but not limited to, any enzyme, variant, nucleic acid, protein, peptide, or cofactor that is at least partially removed from one or more or all of the natural components with which it is associated in nature; (3) any substance that has been artificially modified relative to the substance found in nature; or (4) any substance that has been modified by increasing the amount of the substance relative to other components with which it is associated in nature (e.g., recombinant products in a host cell; multiple copies of a gene encoding the substance; use of a stronger promoter than the promoter naturally associated with the gene encoding the substance). An isolated substance may be present in a fermentation broth sample.

[0017] Mature Polypeptide: The term "mature polypeptide" refers to a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc. It is known in the art that a host cell may produce a mixture of two or more different mature polypeptides (i.e., having different C-terminal and / or N-terminal amino acids) expressed by the same polynucleotide. It is also known in the art that different host cells process polypeptides differently, and thus one host cell expressing a polynucleotide may produce different mature polypeptides (e.g., having different C-terminal and / or N-terminal amino acids) relative to another host cell expressing the same polynucleotide.

[0018] Mature polypeptide coding sequence: The term "mature polypeptide coding sequence" means a polynucleotide that encodes a mature polypeptide.

[0019] Nucleic Acid Construct: The term "nucleic acid construct" refers to a nucleic acid molecule, either single-stranded or double-stranded, that is isolated from a naturally occurring gene or that has been modified to contain a segment of nucleic acid in a manner that would not normally occur in nature or in a synthetic manner, including one or more regulatory sequences.

[0020] Operably linked: The term "operably linked" refers to a configuration in which a control sequence is positioned relative to a coding sequence of a polynucleotide in an appropriate position so as to direct expression of the coding sequence.

[0021] Sequence identity: The relatedness between two amino acid sequences or between two nucleotide sequences is expressed by the parameter "sequence identity". For the purposes of the present invention, the degree of sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48:443-453), preferably as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16:276-277), version 5.0.0 or later. The parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5 and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of the Needle labelled "longest identity" (obtained using the -nobrief option) is used as the identity percentage, calculated as follows: (equivalent residues × 100) / (length of alignment-total number of gaps in alignment)

[0022] For the purposes of the present invention, the degree of sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, supra, 1970), preferably as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, supra, Rice et al., 2000), version 5.0.0 or later. The parameters used are a gap open penalty of 10, a gap extension penalty of 0.5 and the EDNAFULL (EMBOSS version in NCBI NUC4.4) substitution matrix. The output of the Needle labelled "longest identity" (obtained using the -nobrief option) is used as the percentage identity, calculated as follows: (equivalent deoxyribonucleotides × 100) / (length of alignment − total number of gaps in the alignment)

[0023] host cell The present invention relates to recombinant host cells containing a polynucleotide of the present invention operably linked to one or more control sequences that direct the production and secretion of a heterologous polypeptide of interest.

[0024] The construct or vector containing the polynucleotide is introduced into a host cell so that it is maintained as a chromosomal integrant or a self-replicating extrachromosomal vector, as described above. The term "host cell" includes any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication. The choice of host cell will depend in large part on the gene encoding the polypeptide and its source.

[0025] The host cell may be a fungal cell. "Fungi" as used herein includes Ascomycota, Basidiomycota, Chytridiomycota, and Zygomycota, as well as Oomycota and all vegetative spore-forming fungi (as defined by Hawksworth et al., In, Ainsworth and Bisby's Dictionary of The Fungi, 8th edition, 1995, CAB International, University Press, Cambridge, UK).

[0026] The fungal host cells of the present invention are filamentous fungal cells. "Filamentous fungi" includes all filamentous forms of the subdivision Eumycota and Oomycota (as defined by Hawksworth et al., 1995, supra). Filamentous fungi are generally characterized by a mycelial wall composed of chitin, cellulose, glucan, chitosan, mannan, and other complex polysaccharides. Vegetative growth is by hyphal elongation and carbon catabolism is obligately aerobic.

[0027] Filamentous fungal host cells include Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, The cell may be a Neocallimastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes, or Trichoderma cell.

[0028] For example, filamentous fungal host cells include Aspergillus aculeatus, Aspergillus aculetinus, Aspergillus awamori, Aspergillus brasiliensis, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus luchuensis, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa, Ceriporiopsis subvermispora, Chrysosporium inops, Chrysosporium keratinophilum keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicumqueenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negunji negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa lanuginosa, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum, White rot fungus, PhanerochaeteThe cell may be a Trichoderma chrysosporium, Phlebia radiata, Pleurotus eryngii, Thielavia terrestris, Trametes villosa, Trametes versicolor, Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma viride cell.

[0029] Fungal cells may be transformed by a process involving protoplast formation, transformation of the protoplasts, and regeneration of the cell wall in a manner known per se. Methods suitable for transformation of Aspergillus and Trichoderma host cells are described in EP 238023, Yelton et al., 1984, Proc. Natl. Acad. Sci. USA 81:1470-1474, and Christensen et al., 1988, Bio / Technology 6:1419-1422. Methods suitable for transformation of Fusarium species are described by Malardier et al., 1989, Gene 78:147-156, and WO 96 / 00787.

[0030] In one aspect, the invention relates to a mutant filamentous fungal host cell producing a secreted polypeptide of interest, wherein a putative native steroid dehydrogenase has been modified, truncated, partially or completely inactivated, present at a reduced level compared to the non-mutated parent cell or has been eliminated, and wherein said putative native steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; preferably, at least two of the conserved motifs; more preferably, at least three or four of the conserved motifs; and most preferably, all five of the conserved motifs.

[0031] In preferred embodiments of this aspect of the invention, the filamentous fungal host cell is selected from the group consisting of Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocalli, Sclerotium ... More preferably, the filamentous fungal host cell belongs to a genus selected from the group consisting of Aspergillus aculeatus, Aspergillus limastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes, or Trichoderma; even more preferably, the filamentous fungal host cell belongs to a genus selected from the group consisting of Aspergillus aculeatus, Aspergillus limastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes, or Trichoderma; aculeatus, Aspergillus aculetinus, Aspergillus awamori, Aspergillus brasiliensis, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus ryukyuensisluchuensis, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Bjerkandera adusta, Ceriporiopsis aneirina, Ceriporiopsis caregiea, Ceriporiopsis gilvescens, Ceriporiopsis pannocinta, Ceriporiopsis rivulosa, Ceriporiopsis subrufa, Ceriporiopsis subbermispora subvermispora, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zonatum, Coprinus cinereus, Coriolus hirsutus, Fusarium bactridioides bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearumgraminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fusarium oxysporum, Fusarium reticulatum, Fusarium roseum, Fusarium sambucinum, Fusarium sarcochroum, Fusarium sporotrichioides, Fusarium sulphureum, Fusarium torulosum, Fusarium trichothecioides trichothecioides, Fusarium venenatum, Humicola insolens, Humicola lanuginosa, Mucor miehei, Myceliophthora thermophila, Neurospora crassa, Penicillium purpurogenum, White rot fungus, Phlebia radiata, Pleurotus eryngii, Thielavia terrestris, Trametes villosa, Trametes versicolor versicolor), Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reeseireesei, or Trichoderma viride cells.

[0032] Preferably, the secreted polypeptide of interest is native or heterologous; preferably, the secreted polypeptide is an enzyme; preferably, the enzyme is a hydrolase, isomerase, ligase, lyase, oxidoreductase, or transferase, such as an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellobiohydrolase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, or ribonuclease. The enzyme is selected from the group consisting of nuclease, endoglucanase, esterase, α-galactosidase, β-galactosidase, glucoamylase, α-glucosidase, β-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectin degrading enzyme, peroxidase, phospholipase, phytase, polyphenol oxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, and β-xylosidase.

[0033] In a preferred embodiment of the invention, the putative naturally occurring steroid dehydrogenase comprises or consists of an amino acid sequence that is at least 60% identical to the mature amino acid sequence shown in SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and / or SEQ ID NO:12; preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or most preferably at least 99% identical to the mature amino acid sequence shown in SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and / or SEQ ID NO:12.

[0034] Preferably, the putative naturally occurring steroid dehydrogenase is encoded by a gene comprising or consisting of a nucleotide sequence that is at least 60% identical to the genomic DNA sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and / or SEQ ID NO:10; preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or most preferably at least 99% identical to the genomic DNA sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and / or SEQ ID NO:10.

[0035] Alternatively, the putative naturally occurring steroid dehydrogenase is encoded by a gene comprising or consisting of a nucleotide sequence that is at least 60% identical to the cDNA sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and / or SEQ ID NO:11; preferably at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or most preferably at least 99% identical to the cDNA sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and / or SEQ ID NO:11.

[0036] In preferred embodiments, the putative native steroid dehydrogenase is modified, truncated, partially or completely inactivated, present at reduced levels compared to the non-mutated parent cell, or eliminated by a nonsense or frameshift mutation in the encoding gene, by partial or complete deletion of the encoding gene, or by silencing of the encoding gene.

[0037] In a second aspect, the present invention provides a method for producing a mutant filamentous fungal host cell having an improved yield of a secreted polypeptide of interest compared to a non-mutated parent host cell, comprising, in no particular order: a) transforming a filamentous fungal host cell with a polynucleotide construct encoding a secreted polypeptide of interest; b) mutating the host cell to modify, truncate, partially or completely inactivate, reduce the level of, or eliminate a putative naturally occurring steroid dehydrogenase, wherein said putative naturally occurring steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; preferably at least two of the conserved motifs; more preferably at least three or four of the conserved motifs; and most preferably all five of the conserved motifs. It concerns the method.

[0038] nucleic acid construct The present invention also relates to nucleic acid constructs comprising a polynucleotide of the invention operably linked to one or more control sequences which direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.

[0039] Polynucleotides may be manipulated in a variety of ways to result in expression of a polypeptide. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. Techniques for modifying polynucleotides using recombinant DNA methods are known in the art.

[0040] The control sequence may be a promoter, which is a polynucleotide recognized by a host cell for expression of a polynucleotide encoding a polypeptide of the invention. The promoter contains transcriptional control sequences that mediate expression of the polypeptide. The promoter may be any polynucleotide that exhibits transcriptional activity in the host cell, including mutant, truncated and hybrid promoters, and may be derived from genes encoding extracellular or intracellular polypeptides that are homologous or heterologous to the host cell.

[0041] Examples of suitable promoters for directing the transcription of a nucleic acid construct of the invention in a filamentous fungal host cell include the following: Aspergillus nidulans acetamidase (amdS), Aspergillus oryzae neutral α-amylase (e.g., amyB), Aspergillus oryzae acid-stable α-amylase (asaA), Aspergillus oryzae or Aspergillus awamori glucoamylase (glaA), Aspergillus oryzae TAKA amylase, Aspergillus oryzae alkaline protease (alpA), Aspergillus oryzae oryzae triosephosphate isomerase (tpiA), Fusarium oxysporum trypsin-like protease (WO 96 / 00787), Fusarium venenatum amyloglucosidase (WO 00 / 56900), Fusarium venenatum Daria (WO 00 / 56900), Fusarium venenatum Quinn (WO 00 / 56900), Rhizomucor miehei lipase, Rhizomucor miehei aspartic proteinase, Trichoderma reesei reesei β-glucosidase, Trichoderma reesei cellobiohydrolase I, Trichoderma reesei cellobiohydrolase II, Trichoderma reesei endoglucanase I, Trichoderma reeseireesei endoglucanase II, Trichoderma reesei endoglucanase III, Trichoderma reesei endoglucanase V, Trichoderma reesei xylanase I, Trichoderma reesei xylanase II, Trichoderma reesei xylanase III, Trichoderma reesei β-xylosidase, and Trichoderma reesei reesei translation elongation factor, and the NA2-tpi promoter (a modified promoter from the Aspergillus neutral α-amylase gene in which the non-translated leader has been replaced with the non-translated leader from the Aspergillus triose phosphate isomerase gene; non-limiting examples include the modified promoter from the Aspergillus oryzae neutral α-amylase gene in which the non-translated leader has been replaced with the non-translated leader from the Aspergillus nidulans or Aspergillus oryzae triose phosphate isomerase gene); and mutants, truncations and hybrid promoters thereof. Other promoters are described in U.S. Pat. No. 6,011,147.

[0042] The control sequence may also be a transcription terminator that is recognized by a host cell to terminate transcription. The terminator is operably linked to the 3'-end of the polynucleotide encoding the polypeptide. In the present invention, any terminator that functions in the host cell may be used.

[0043] Preferred terminators for filamentous fungal host cells are obtained from the following genes: Aspergillus nidulans acetamidase, Aspergillus nidulans anthranilate synthase, Aspergillus oryzae glucoamylase, Aspergillus oryzae α-glucosidase, Aspergillus oryzae TAKA amylase, Fusarium oxysporum trypsin-like protease, Trichoderma reesei β-glucosidase, Trichoderma reesei cellobiohydrolase I, Trichoderma reesei β-glucosidase ... reesei cellobiohydrolase II, Trichoderma reesei endoglucanase I, Trichoderma reesei endoglucanase II, Trichoderma reesei endoglucanase III, Trichoderma reesei endoglucanase V, Trichoderma reesei xylanase I, Trichoderma reesei xylanase II, Trichoderma reesei xylanase III, Trichoderma reesei β-xylosidase, and Trichoderma reesei translation elongation factor.

[0044] A regulatory sequence may also be an mRNA stabilizing region downstream of a promoter and upstream of the coding sequence of a gene, which increases expression of the gene.

[0045] The control sequence may also be a leader, i.e., a non-translated region of an mRNA, which is important for translation by the host cell. The leader is operably linked to the 5'-end of the polynucleotide encoding the polypeptide. Any leader may be used, provided it is functional in the host cell.

[0046] Preferred leaders for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulans triose phosphate isomerase.

[0047] The control sequence may also be a polyadenylation sequence, which is a sequence operably linked to the 3'-end of a polynucleotide and, when transcribed, is recognized by a host cell as a signal for loading polyadenosine residues onto the transcribed mRNA. Any polyadenylation sequence that functions in the host cell may be used.

[0048] Preferred polyadenylation sequences for filamentous fungal host cells are obtained from the genes for Aspergillus nidulans anthranilate synthase, Aspergillus oryzae glucoamylase, Aspergillus oryzae α-glucosidase, Aspergillus oryzae TAKA amylase, and Fusarium oxysporum trypsin-like protease.

[0049] The control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a polypeptide and directs the polypeptide into the secretory pathway of a cell. The 5'-end of the coding sequence of a polynucleotide may inherently contain a signal peptide coding sequence naturally linked in translation reading frame with the segment of the coding sequence that encodes the polypeptide. Alternatively, the 5'-end of the coding sequence may contain a signal peptide coding sequence foreign to the coding sequence. A foreign signal peptide coding sequence may be required when the coding sequence does not naturally contain a signal peptide coding sequence. Alternatively, the foreign signal peptide coding sequence may simply replace a natural signal peptide coding sequence to enhance secretion of the polypeptide. However, any signal peptide coding sequence that directs an expressed polypeptide into the secretory pathway of a host cell may be used.

[0050] Effective signal peptide coding sequences for filamentous fungal host cells are those obtained from the genes for Aspergillus oryzae neutral amylase, Aspergillus oryzae glucoamylase, Aspergillus oryzae TAKA amylase, Humicola insolens cellulase, Humicola insolens endoglucanase V, Humicola lanuginosa lipase, and Rhizomucor miehei aspartic proteinase.

[0051] The control sequence may also be a propeptide coding sequence that codes for a propeptide position at the N-terminus of a polypeptide. The resulting polypeptide is known as a zymogen or propolypeptide (or, in some cases, a zymogen). A propolypeptide is generally inactive and can be converted to an active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. Propeptide coding sequences can be obtained from the genes for Bacillus subtilis alkaline protease (aprE), Bacillus subtilis neutral protease (nprT), Myceliophthora thermophila laccase (WO 95 / 33836), Rhizomucor miehei aspartic proteinase, and Saccharomyces cerevisiae α-factor.

[0052] When both a signal peptide and a propeptide sequence are present, the propeptide sequence is positioned adjacent to the N-terminus of the polypeptide and the signal peptide sequence is positioned adjacent to the N-terminus of the propeptide sequence.

[0053] It may be desirable to add regulatory sequences that regulate the expression of the polypeptide relative to the growth of the host cell. Examples of regulatory sequences are those that turn the expression of a gene on or off in response to a chemical or physical stimulus, including the presence of a regulatory compound. In filamentous fungi, the Aspergillus oryzae glucoamylase promoter, the Aspergillus oryzae TAKA alpha-amylase promoter, and the Aspergillus oryzae glucoamylase promoter, the Trichoderma reesei cellobiohydrolase I promoter, and the Trichoderma reesei cellobiohydrolase II promoter may be used. Other examples of regulatory sequences are those that allow for gene amplification. In eukaryotic systems, these regulatory sequences include the dihydrofolate reductase gene, which is amplified in the presence of methotrexate, and the metallothionein gene, which is amplified with heavy metals. In these cases, the polynucleotide encoding the polypeptide would be operably linked with the regulatory sequence.

[0054] Expression vector The present invention also relates to a recombinant expression vector comprising the polynucleotide of the present invention, a promoter, and transcription and translation termination signals. Various nucleotides and control sequences are combined to produce a recombinant expression vector that may contain one or more convenient restriction sites to allow for the insertion or replacement of a polynucleotide encoding a polypeptide at such site. Alternatively, a polynucleotide may be expressed by inserting a polynucleotide or a nucleic acid construct comprising a polynucleotide into a vector suitable for expression. In forming an expression vector, a coding sequence is positioned in a vector such that the coding sequence is operably linked to a control sequence suitable for expression.

[0055] The recombinant expression vector may be any vector (e.g., a plasmid or a virus) that can be conveniently subjected to recombinant DNA techniques and that can bring about the expression of a polynucleotide. The choice of vector will typically depend on the affinity of the vector for the host cell into which it is to be introduced. The vector may be a linear or closed circular plasmid.

[0056] The vector may be an autonomously replicating vector (i.e., a vector that exists as an extrachromosomal entity and whose replication is independent of chromosomal replication), such as a plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain some means for ensuring autonomous replication. Alternatively, the vector may be one that, when introduced into a host cell, is integrated into the genome and replicated together with the chromosome into which it is integrated. Moreover, a single vector or plasmid, or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell, or a transposon may be used.

[0057] Vectors preferably contain one or more selectable markers which facilitate the selection of cells that have been transformed, transfected, transduced, etc. A selectable marker is a gene the product of which confers biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like.

[0058] - Selectable markers for use in filamentous fungal host cells include, but are not limited to, adeA (phosphoribosylaminoimidazole-succinocarboxamide synthase), adeB (phosphoribosyl-aminoimidazole synthase), amdS (acetamidase), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), and trpC (anthranilate synthase), and equivalents thereof. The Aspergillus nidulans or Aspergillus oryzae amdS and pyrG genes and the Streptomyces hygroscopicus bar gene are preferred for use in an Aspergillus cell. The adeA, adeB, amdS, hph, and pyrG genes are preferred for use in a Trichoderma cell.

[0059] The selection marker may be a double selection marker system as described in WO 2010 / 039889. In one embodiment, the double selection marker is the hph-tk double selection marker system.

[0060] Preferably, the vector contains elements that allow for integration of the vector into the genome of the host cell, or for autonomous replication of the vector in the cell independent of the genome.

[0061] For integration into the host cell genome, the vector may rely on the sequence of the polynucleotide encoding the polypeptide or any other element of the vector for integration into the genome by homologous or non-homologous recombination. Alternatively, the vector may contain additional polynucleotides that result in integration by homologous recombination into the genome of the host cell at a precise location in the chromosome. To increase the chance of integration at a precise location, the integration element should contain a sufficient number of nucleic acids, such as 100-10,000 base pairs, 400-10,000 base pairs, and 800-10,000 base pairs, with a high degree of sequence identity to the corresponding target sequence to increase the probability of homologous recombination. The integration element may be any sequence that is homologous to the target sequence in the genome of the host cell. Furthermore, the integration element may be a non-coding or coding polynucleotide. On the other hand, the vector may be integrated into the genome of the host cell by non-homologous recombination.

[0062] Another efficient method to ensure site-specific genomic integration is the use of FRT sites, e.g., FRT-F and FRT-F3, inserted into each of the genomic loci in a site-specific targeted integration of the expression cassette using Saccharomyces cerevisiae flippase (FLP) and FRT flippase recognition sequences, as described in WO 2012 / 160093 and US 2018 / 0037897.

[0063] With regard to autonomous replication, the vector may further comprise an origin of replication that allows the vector to replicate autonomously in a host cell of interest. The origin of replication may be any plasmid replicator that mediates autonomous replication in a cell. The term "origin of replication" or "plasmid replicator" refers to a polynucleotide that allows a plasmid or vector to replicate in vivo.

[0064] Examples of origins of replication useful in filamentous fungal cells are AMA1 and ANS1 (Gems et al., 1991, Gene 98:61-67; Cullen et al., 1987, Nucleic Acids Res. 15:9163-9175; WO 00 / 24883). Isolation of the AMA1 gene and construction of plasmids or vectors containing the AMA1 gene can be accomplished according to the methods disclosed in WO 00 / 24883.

[0065] More than one copy of a polynucleotide of the invention may be inserted into a host cell to enhance production of the polypeptide. The number of copies of the polynucleotide can be increased by integrating at least one additional copy of the sequence into the host cell genome, or by including an amplifiable selectable marker gene in the polynucleotide, where cells containing amplified copies of the selectable marker gene, and thus additional copies of the polynucleotide, can be selected by culturing the cells in an appropriate selectable agent.

[0066] The techniques used to ligate the above-described elements to construct the recombinant expression vectors of the present invention are well known to those of skill in the art (see, for example, Sambrook et al., 1989, supra).

[0067] Elimination or reduction of activity The present invention also relates to a method comprising mutating a host cell to modify, truncate, partially or completely inactivate, reduce the level of or eliminate a putative steroid dehydrogenase, wherein said putative native steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; preferably at least two of the conserved motifs; more preferably at least three or four of the conserved motifs; most preferably, all five of the conserved motifs.

[0068] Mutant cells may be constructed by reducing or eliminating the expression of a polynucleotide or its homologues using methods well known in the art, such as insertion, disruption, substitution, or deletion. In a preferred embodiment, the expression of a polynucleotide is altered, reduced or eliminated. The polynucleotide to be altered, reduced or eliminated may be mutated or modified, for example, in the coding region or a part thereof that is essential for activity, or in a regulatory element required for expression of the coding region. An example of such a regulatory or control sequence may be a promoter sequence or a functional part thereof, i.e. a part sufficient to affect the expression of the polynucleotide. Other control sequences for possible modification include, but are not limited to, leaders, polyadenylation sequences, propeptide sequences, signal peptide sequences, transcription terminators, and transcription activators.

[0069] Modification or inactivation of a polynucleotide may be performed by subjecting a parent cell to mutagenesis and selecting for mutant cells in which expression of the polynucleotide is reduced or eliminated. Mutagenesis may be specific or random, and may be performed, for example, by the use of suitable physical or chemical mutagenizing agents, by the use of suitable oligonucleotides, or by subjecting the DNA sequence to PCR-generated mutagenesis. Furthermore, mutagenesis may be performed by the use of any combination of these mutagenizing agents.

[0070] Examples of physical or chemical mutagenic agents suitable for this purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methylhydroxylamine, nitrous acid, ethyl methanesulfonate (EMS), sodium bisulfite, formic acid, and nucleotide analogs.

[0071] When such agents are used, mutagenesis is typically performed by incubating the parent cells to be mutagenized in the presence of the selected mutagenic agent under suitable conditions, and screening and / or selecting for mutant cells that exhibit reduced or no expression of the gene.

[0072] Modification or inactivation of a polynucleotide or its homologue may be achieved by insertion, substitution or deletion of one or more nucleotides in the gene or in a regulatory element required for its transcription or translation. For example, nucleotides may be inserted or removed to introduce a stop codon, remove the start codon, or cause a change in the open reading frame or intron processing. Such modification or inactivation may be achieved by site-directed mutagenesis or PCR-generated mutagenesis according to methods known in the art. Although in principle the modification may be performed in vivo, i.e. directly on a cell expressing the polynucleotide to be modified, it is preferred that the modification is performed in vitro, as exemplified below.

[0073] Methods for deleting or disrupting targeted genes have been described, for example, by Miller, et al. (1985. Mol. Cell. Biol. 5:1714-1721); WO 90 / 00192; May, G. (1992. Applied Molecular Genetics of Filamentous Fungi. J.R.Kinghorn and G. Turner, eds., Blackie Academic and Professional, pp. 1-25); and Turner, G. (1994. Vectors for Genetic Manipulation. S.D. Martinelli and J.R.Kinghorn, eds., Elsevier, pp. 641-665).

[0074] Examples of convenient methods for eliminating or reducing the expression of a polynucleotide are based on the techniques of gene replacement, gene deletion, gene editing or gene disruption. For example, in gene disruption methods, the nucleic acid sequence corresponding to the endogenous polynucleotide is mutagenized in vitro to generate a defective nucleic acid sequence, and then transformed into the parent cell to generate a defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous polynucleotide. It may be desirable for the defective polynucleotide to also code for a marker that may be used to select transformants in which the polynucleotide has been modified or destroyed. In one aspect, the polynucleotide is disrupted with a selectable marker as described herein.

[0075] The present invention also relates to a method of inhibiting expression of an active polypeptide in a cell comprising administering to or expressing in the cell a double-stranded RNA (dsRNA) molecule, wherein the dsRNA comprises a subsequence of a polynucleotide or a homolog thereof. In preferred embodiments, the dsRNA is about 15, about 16, about 17, about 18, about 19, about 20, about 21, about 22, about 23, about 24, about 25 or more double-stranded nucleotides in length.

[0076] The dsRNA is preferably a small interfering RNA (siRNA) or a microRNA (miRNA). In a preferred embodiment, the dsRNA is a small interfering RNA for inhibiting transcription. In another preferred embodiment, the dsRNA is a microRNA for inhibiting translation.

[0077] The present invention also relates to double-stranded RNA (dsRNA) molecules, such as those comprising a portion of the mature polypeptide coding sequence of SEQ ID NO:1 and / or SEQ ID NO:4 and / or SEQ ID NO:7 and / or SEQ ID NO:10, for inhibiting expression of a polypeptide in a cell. Although the present invention is not limited by any particular mechanism of action, dsRNA can enter a cell and cause degradation of single-stranded RNA (ssRNA) of similar or identical sequence, such as endogenous mRNA. When a cell is exposed to dsRNA, mRNA from a homologous gene is selectively degraded by a process called RNA interference (RNAi); see, e.g., U.S. Pat. No. 5,190,931.

[0078] The dsRNA of the present invention can be used in gene silencing.In one aspect, the present invention provides a method for selectively degrading RNA using the dsRNAi of the present invention.The method can be carried out in vitro, ex vivo or in vivo.In one aspect, the dsRNA molecule can be used to create loss-of-function mutations in cells, organs or animals.The method for creating and using dsRNA molecules to selectively degrade RNA is well known in the art; see, for example, U.S. Patent No. 6,489,127; U.S. Patent No. 6,506,559; U.S. Patent No. 6,511,824 and U.S. Patent No. 6,515,109.

[0079] Protease-deficient mutant cells are particularly useful as host cells for the expression of secreted heterologous polypeptides.

[0080] The methods used for cultivation and purification of the product of interest may be carried out by methods known in the art.

[0081] Production method The host cells are cultured in a nutrient medium suitable for the production of the polypeptide using methods known in the art. For example, the cells can be cultured by shake flask culture and by small- or large-scale fermentation (including continuous, batch, fed-batch or solid-state fermentation) in a suitable medium and under conditions that allow expression and / or isolation of the polypeptide. Cultivation is carried out in a suitable nutrient medium containing carbon and nitrogen sources and inorganic salts using techniques known in the art. Suitable media are available from commercial suppliers or can be prepared according to published compositions (e.g., catalogues of the American Type Culture Collection). If the polypeptide is secreted into the nutrient medium, it can be recovered directly from the medium. If the polypeptide is not secreted, it can be recovered from cell lysates.

[0082] Polypeptides can be detected using methods known in the art that are specific for the polypeptides, including, but not limited to, the use of specific antibodies, the formation of an enzyme product, or disappearance of an enzyme substrate, etc. For example, an enzyme assay may be used to determine the activity of the polypeptide.

[0083] The polypeptide may be recovered using methods known in the art. For example, the polypeptide may be recovered from the nutrient medium by conventional techniques including, but not limited to, collection, centrifugation, filtration, extraction, spray drying, evaporation, or precipitation. In one aspect, the fermentation broth containing the polypeptide is recovered.

[0084] Polypeptides can be purified by a variety of techniques known in the art, including, but not limited to, chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing, and size exclusion), electrophoretic techniques (e.g., preparative isoelectric focusing), differential solubility (e.g., ammonium sulfate precipitation), SDS-PAGE, or extraction (see, e.g., Protein Purification, eds. Janson and Ryden, VCH Publishers, New York, 1989) to obtain substantially pure polypeptides.

[0085] In an alternative embodiment, the polypeptide is not recovered, and a host cell of the invention expressing the polypeptide may be used as the source of the polypeptide.

[0086] One aspect of the invention is a method for producing a secreted polypeptide of interest, comprising the steps of: a) culturing a mutant filamentous fungal host cell according to any preceding claim under conditions practical for the production of a secreted polypeptide; and optionally b) recovering the secreted polypeptide of interest; The present invention relates to a method comprising the steps of:

[0087] In a preferred embodiment, the filamentous fungal host cell is selected from the group consisting of Acremonium, Aspergillus, Aureobasidium, Bjerkandera, Ceriporiopsis, Chrysosporium, Coprinus, Coriolus, Cryptococcus, Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor, Myceliophthora, Neocalli, and the like. mastix, Neurospora, Paecilomyces, Penicillium, Phanerochaete, Phlebia, Piromyces, Pleurotus, Schizophyllum, Talaromyces, Thermoascus, Thielavia, Tolypocladium, Trametes and Trichoderma; even more preferably, the filamentous fungal host cell is an Aspergillus cell;Preferred are Aspergillus aculeatus, Aspergillus aculetinus, Aspergillus awamori, Aspergillus brasiliensis, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus luchuensis, Aspergillus nidulans, Aspergillus niger, and Aspergillus oryzae.

[0088] Preferably, the secreted polypeptide of interest is an enzyme; preferably the enzyme is a hydrolase, isomerase, ligase, lyase, oxidoreductase, or transferase, such as an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellobiohydrolase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, endoglucanase, esterase, α-galactosidase, β-galactosidase, glucoamylase, α-glucosidase, β-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectolytic enzyme, peroxidase, phytase, polyphenol oxidase, proteolytic enzyme, ribonuclease, transglutaminase, xylanase, or β-xylosidase. EXAMPLES

[0089] Filamentous fungal strains Trichoderma reesei BTR213 is described in WO 2013 / 086633.

[0090] Trichoderma reesei strain frt4new-1940-1996-2012-12-1 is a ku70 disrupted and paracelsin synthetase (parS) deletion strain of T. reesei BTR213. The cellobiohydrolase I (cbh1), cellobiohydrolase II (cbh2), endoglucanase I (eg1), and xylanase II (xyn2) genes have been deleted in this strain, with FRT sites (FRT-F and FRT-F3) inserted into each of these four loci for site-specific targeted integration of expression cassettes using Saccharomyces cerevisiae flippase (FLP) and flippase recognition sequences FRT-F and FRT-F3, as described in WO 2012 / 160093 and US 2018 / 0037897. The endoglucanase II gene (eg2) and endoglucanase III gene (eg3) are similarly deleted in this strain. The Aspergillus niger cytosine deaminase (fcyA) gene was inserted between the FRT-F and FRT-F3 sites at each of the four loci and used as counterselection against 5-fluorocytosine (5-FC).

[0091] Media and Solutions COVE plates consisted of 342.30 g sucrose, 25 g Difco™ Noble agar, 20 ml COVE salts solution, 10 mM acetamide, 15 mM cesium chloride, and deionized water, brought to 1 L. The solution was sterilized by autoclaving.

[0092] COVE2 plates consisted of 30 g sucrose, 20 ml COVE salts solution, 10 ml 1 M acetamide, 25 g Difco™ Noble agar, and deionized water, brought to 1 L. The solution was sterilized by autoclaving.

[0093] COVE2 glucose plates containing 5-fluorocytosine (5-FC) (Sigma Chemical Co.) consisted of 20 ml of COVE salts solution, 10 ml of 1 M acetamide, 25 g of Difco™ Noble agar, and deionized water, brought to 1 liter. The solution was sterilized by autoclaving. After autoclaving, 40 ml of 50% (w / v) glucose (sterile) was added. The solution was cooled to 50° C. and 5-FC was added to a final concentration of 75 μg / ml.

[0094] The COVE salt solution is 26 g KCl, 26 g MgSO 4 7H 2 O, 76g KH 2 PO 4 The solution consisted of 50 ml of COVE trace metals solution and deionized water to 1 L. The solution was sterilized by autoclaving.

[0095] The COVE trace metals solution contains 0.04 g Na 2 B 4 O 7 10H 2 0, 0.4 g CuSO 4 5H 2 o, 1.2 g FeSO 4 7H 2 0, 0.7 g MnSO 4 H 2 O, 0.8 g Na 2 MoO 2 2H 2 0, 10 g ZnSO 4 7H 2 0, and deionized water to 1 L. The solution was sterilized by autoclaving.

[0096] The fermentation batch medium consisted of 24 g dextrose, 40 g defatted soybeans, 8 g (NH4 ) 2 SO 4 , 3g K 2 HPO 4 , 8g of K 2 SO 4 , 3 g CaCO 3 , 8g MgSO 4 7H 2 O, 1 g citric acid, 8.8 ml 85% phosphoric acid, 1 ml antifoam, 14.7 ml trace metals solution, and deionized water to 1 liter.

[0097] PDA plates consisted of 39 g of Difco™ Potato Dextrose Agar and deionized water, brought to 1 liter. The solution was sterilized by autoclaving.

[0098] PDA+1M sucrose plates consisted of 39 g Difco™ Potato Dextrose Agar, 342.30 g sucrose and deionized water, brought to 1 L. The solution was sterilized by autoclaving.

[0099] PEG buffer was 50% polyethylene glycol (PEG) 4000, 10 mM Tris-HCl, pH 7.5, and 10 mM CaCl in deionized water. 2 The solution was filter sterilized.

[0100] Sample buffer (pH 7.5) consisted of 0.1 M Tris-HCl, 0.1 M NaCl, and 0.01% Triton X100. The solution was filter sterilized. Shake flask medium consisted of 20 g glycerol, 10 g defatted soybeans, 1.5 g (NH 4 ) 2 SO 4 , 2g KH 2 PO 4 , 0.2 g CaCl 2 , 0.4g MgSO 4 7H 2 0, 0.2 ml of trace metals solution, and deionized water to 1 liter.

[0101] 1.2 M sorbitol consisted of 218.4 g sorbitol and deionized water, brought to 1 L. The solution was sterilized by autoclaving.

[0102] STC was prepared in deionized water, containing 1 M sorbitol, 10 mM Tris-HCl, pH 7.5, and 50 mM CaCl 2 The solution was filter sterilized.

[0103] TBE buffer consisted of 10.8 g Tris base, 5 g boric acid, 4 ml 0.5 M EDTA, pH 8, and deionized water, made up to 1 liter.

[0104] TE buffer consists of 1 M Tris-HCl, pH 8.0 and 0.5 M EDTA, pH 8.0.

[0105] The trace metals solution consisted of 26.1 g of FeSO 4 7H 2 0, 5.5 g ZnSO 4 7H 2 O, 6.6 g MnSO 4 H 2 0, 2.6 g CuSO 4 5H 2 The solution consisted of 0, 2 g citric acid, and deionized water, brought to 1 liter. The solution was sterilized by autoclaving.

[0106] Trichoderma minimal medium (TrMM) plates with 1.5 μM 5-fluoro-2'-deoxyuridine (FdU) were plated on 20 ml of COVE salts solution, 0.6 g of CaCl 2 2H 2 O, 6 g (NH 4 ) 2 SO 4 The medium consisted of 100% PBS, 25 g Difco™ Noble agar, and deionized water to 1 liter. The solution was sterilized by autoclaving. After autoclaving, 40 ml of sterile 50% (w / v) glucose was added. The medium was cooled to 50° C. and FdU (sterile) was added to a final concentration of 1.5 μM.

[0107] 2xYT+Amp plates consisted of 16 g Bacto™ Tryptone, 10 g Bacto™ Yeast Extract, 5 g NaCl, 15 g Bacto™ Agar, 1 ml Ampicillin at 100 mg / ml (filter sterilized and added after autoclaving), and deionized water, brought to 1 liter. The solution was sterilized by autoclaving.

[0108] YP medium consisted of 1% Bacto™ yeast extract and 2% Bacto™ peptone in deionized water. The solution was sterilized by autoclaving.

[0109] YPD medium consisted of 1% Bacto™ yeast extract, 2% Bacto™ peptone and 2% glucose. The solution was sterilized by autoclaving.

[0110] The fermentation feed medium was 1190 g glucose, 14.2 ml 85% H 3 PO 4 and 486g of H 2 The solution consisted of 0.02% ethanol and 10% ethanol. The solution was sterilized by autoclaving.

[0111] Example 1: Genomic DNA extraction from Trichoderma reesei Trichoderma reesei was grown in 50 ml of YPD medium in 250 ml baffled shake flasks at 28°C for 2 days with agitation at 200 rpm. Mycelia from the cultures were collected using a MIRACLOTH® (EMD Chemicals Inc.) series funnel, squeezed dry, and then transferred to a pre-chilled mortar and pestle. Each mycelial preparation was ground to a fine powder and kept frozen in liquid nitrogen. A total of 1-2 g of powder was transferred to a 50 ml tube, and genomic DNA was extracted from the ground mycelial powder using the DNEASY® Plant Maxi kit (QIAGEN Inc.). Five ml of Buffer AP1 (QIAGEN Inc.) pre-heated to 65°C, followed by 10 μl of a 100 mg / ml stock solution of ribonuclease A (QIAGEN Inc.) was added to the 50 ml tube and incubated at 65°C for 2-3 hours. A total of 1.8 ml of AP2 buffer (QIAGEN Inc.) was added and centrifuged at 3000-5000 x g for 5 min. The supernatant was decanted into a QIAshredder Maxi spin column (QIAGEN Inc.) placed in a 50 ml collection tube and centrifuged at 3000-5000 x g for 5 min in a swing-out rotor at room temperature (15-25 °C). The flow-through in the collection tube was transferred to a new 50 ml tube without disturbing the pellet. A volume of 1.5 ml of buffer AP3 / E (QIAGEN Inc.) was added to the clarified lysate and immediately mixed by vortexing. The sample (up to 15 ml), including any precipitate that may have formed, was pipetted into a DNEASY® Maxi spin column (QIAGEN Inc.) in a 50 ml collection tube and centrifuged at 3000-5000 x g for 5 min in a swing-out rotor at room temperature (15-25 °C). The flow-through was discarded. 12 ml of Buffer AW (QIAGEN Inc.) was added to the DNEASY® Maxi spin column and centrifuged at 3000-5000 x g for 10 min to dry the membrane. The flow-through and collection tube were discarded. The DNEASY® Maxi spin column was transferred to a new 50 ml tube.0.5 ml of Buffer AE (QIAGEN Inc.) preheated to 65°C was pipetted directly onto the DNEASY® Maxi spin column membrane, incubated at room temperature (15-25°C) for 5 min, and then centrifuged at 3000-5000 x g for 5 min to elute the genomic DNA. The concentration and purity of the genomic DNA were determined by measuring the absorbance at 260 nm and 280 nm.

[0112] Example 2: Preparation and transformation of protoplasts of Trichoderma reesei Preparation and transformation of Trichoderma reesei protoplasts was performed using a protocol similar to Penttila et al., 1987, Gene 61:155-164. Briefly, T. reesei was grown in two shake flasks (each containing 25 ml of YPD medium) at 27°C with gentle agitation at 90 rpm for 17 h. Mycelia were harvested by filtration using a vacuum-driven disposable filtration system (Millipore) and washed twice with deionized water and twice with 1.2 M sorbitol. Protoplasts were generated by suspending the washed mycelia in 30 ml of 1.2 M sorbitol containing 5 mg / ml Yatalase™ (Takara Bio USA, Inc.) and 0.5 mg / ml Chitinase (Sigma Chemical Co.) with slow shaking at 75-90 rpm for 60-75 min at 34°C. Protoplasts were collected by centrifugation at 834 × g for 6 min and washed twice with chilled 1.2 M sorbitol. Protoplasts were counted using a hemocytometer and counted to a final concentration of 1 × 10 8 The cells were resuspended in STC at 100 protoplasts / ml.

[0113] Approximately 1-10 μg of DNA was added to 100 μl of protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34 °C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30 °C for 7-9 days. For DNA containing the hygromycin B resistance marker (hph), the contents were spread onto PDA + 1M sucrose plates and incubated overnight at 30 °C. The next day, an overlay consisting of PDA + hygromycin B was added to a final concentration of 10 μg / ml hygromycin B, and the plates were incubated at 30 °C for 5-7 days.

[0114] Example 3: Construction of a plasmid (pNJOC577; SEQ ID NO: 13) for modification of the TrA1331W gene (SEQ ID NO: 1) encoding a putative steroid dehydrogenase A plasmid intended for the modification of the protein encoded by TrA1331W (SEQ ID NO: 1) by the introduction of mutations resulting in either a truncation or an internal deletion of several consecutive amino acids within the region encoding the putative steroid dehydrogenase domain was constructed by cloning the 5' targeting region, the hph (hygromycin phosphotransferase) and tk (HSV-1 thymidine kinase) cassettes, the repeats to be used for the excision of the hph and tk cassettes, and the 3' targeting region into pUC19 (linearized with HindIII and SacI) using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England Biolabs®, Inc.). The 5' targeting region, the hph and tk cassettes, the repeats for the excision of the hph and tk cassettes, and the 3' targeting region were amplified using the primer set: oNJ587 (SEQ ID NO: 19) + oNJ605 (SEQ ID NO: 20), oNJ610 (SEQ ID NO: 25) + oNJ611 (SEQ ID NO: 26), oNJ606 (SEQ ID NO: 21) + oNJ607 (SEQ ID NO: 22), and oNJ608 (SEQ ID NO: 23) + oNJ609 (SEQ ID NO: 24) was used for PCR amplification.

[0115] Amplification reactions were carried out using Phusion® Hot Start II DNA polymerase (Thermo Fisher Scientific) according to the manufacturer's instructions. PCR consisted of 5 ng of pJfyS1579-41-11 (WO 2010 / 039840) (template for the hph / tk cassette) or 50 ng of BTR213 genomic DNA (WO 2013 / 086633) as template, 1× HF buffer, 200 μM of each dNTP, 500 nM of forward primer, 500 nM of reverse primer, 1 unit of Phusion® Hot Start II DNA polymerase and sterile Milli-Q® H 2 O was added to a final volume of 50 μl. The reactions were incubated in a Bio-Rad C1000 Touch™ thermal cycler (Bio-Rad Laboratories) programmed for 1 cycle at 98° C. for 3 min; 35 cycles each of 98° C. for 10 s, 65° C. for 30 s, and 72° C. for 30 s (repeat fragments) or 2.5 min; and 1 cycle at 72° C. for 5 min. After thermocycling, the PCR products were separated by 1% agarose gel electrophoresis in TBE buffer, and bands corresponding to the different PCR products (2354 bp, 4395 bp, 322 bp, and 1986 bp) were excised from the gel and purified using NucleoSpin® Gel and PCR clean-up kit (Macherey-Nagel) according to the manufacturer's instructions. pUC19 was diluted with 5 μg of pUC19, 20 units each of HindIII-HF (New England Biolabs®, Inc.) and SacI-HF (New England Biolabs®, Inc.), 1× CutSmart® buffer (New England Biolabs®, Inc.) and sterile Milli-Q® H 2The pUC19 HindIII / SacI fragment was digested with HindIII and SacI in a 50 μl reaction consisting of 0 and a final volume of 50 μl. The reaction was incubated at 37° C. and then subjected to 1% agarose gel electrophoresis in TBE buffer. The 2645 bp pUC19 HindIII / SacI fragment was excised from the gel and purified using NucleoSpin® Gel and PCR Cleanup Kit (Macherey-Nagel) according to the manufacturer's instructions. The PCR product and the pUC19 HindIII / SacI fragment were fused together using a NEBuilder® HiFi DNA Assembly Master Mix kit (New England Biolabs) in a total volume of 30 μL consisting of 1× NEBuilder® HiFi Assembly Master Mix and 0.04 pmoles of PCR product each. The reaction was incubated at 50° C. for 45 minutes and then placed on ice. One μL of the reaction was used to transform 60 μL of Stellar™ competent cells (Clontech Laboratories, Inc.) according to the manufacturer's instructions. The transformation reaction was spread onto two 2xYT+Amp plates and incubated overnight at 37° C. Putative transformant colonies were isolated from the selection plates and plasmid DNA was prepared from each using a QIAprep Spin Miniprep kit (Qiagen) and screened for proper insertion of the fragment by digestion with PvuII. Plasmid DNA that gave the expected band pattern upon restriction enzyme digestion (4991 bp, 3362 bp, 2364 bp, 439 bp and 370 bp) was used to generate paired-end sequencing libraries and sequenced using 2×150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module. Reads were mapped to a model of the pNJOC577 plasmid (SEQ ID NO: 13) using Map Read against a reference module at high stringency settings.The Basic Variant Detection module was used to detect the presence of any single nucleotide polymorphisms.The plasmid with the predicted nucleotide sequence was named pNJOC577 (Figure 1).

[0116] Example 4: Construction of a Trichoderma reesei strain with modification of the protein encoded by TrA1331W (NJOC586) Trichoderma reesei frt4new-1940-1996-2012-12-1 protoplasts were generated as described in Example 2. Approximately 2-4 μg of linearized TrA1331W modified cassette from pNJOC577 (8871 bp PmeI fragment) was added to 100 μl of protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction was mixed and incubated at 34 °C for 30 min. STC (1 ml) was then added and the contents were spread onto PDA + 1M sucrose plates and incubated overnight at 30 °C. The next day, an overlay consisting of PDA + hygromycin B was added to a final concentration of 10 μg / ml hygromycin B and the plates were incubated at 30 °C for 5-7 days. Hygromycin-resistant transformants were then transferred to PDA plates and incubated at 30 °C for 5-7 days. Transformants were screened for correct integration of the TrA1331 modification cassette by spore PCR. For each transformant, spores were collected using a sterile 1 μl inoculation loop and suspended in 20 μl of dilution buffer (PHIRE™ Plant Direct PCR Kit, Thermo Scientific) in a thin-walled PCR tube. Each spore suspension was used as a template in a PCR reaction to screen for integration of the TrA1331W modification cassette at the TrA1331W locus. Two PCRs were performed for each transformant; one for the 5′ site of integration and one for the 3′ site of integration. Screening for 5′ integration was performed with a primer annealing to the upstream region of the integration site and a primer annealing to a region inside the hph and tk cassettes. Screening for 3′ integration was performed with a primer annealing to the downstream region of the integration site and a primer annealing to a region inside the hph and tk cassettes.Each PCR reaction contained 1 μl of spore suspension, 10 pmoles of each primer, 10 μl of 2x PHIRE™ Plant PCR Buffer (PHIRE™ Plant Direct PCR Kit, Thermo Scientific), 0.4 μl of PHIRE™ Hot Start II DNA Polymerase (PHIRE™ Plant Direct PCR Kit, Thermo Scientific) and H. 2 The PCR products were then analyzed by 1% agarose gel electrophoresis using TBE buffer to a final volume of 20 μl. Thermocycling was performed according to the manufacturer's instructions. PCR products were analyzed by 1% agarose gel electrophoresis using TBE buffer. Transformants yielding the desired PCR product were then subjected to single spore isolation on PDA+1M sucrose plates. Plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to a new PDA plate and plates were incubated at 30°C for 5-7 days. The above 5' and 3' integration verification PCR was repeated and PCR products were analyzed by 1% agarose gel electrophoresis using TBE buffer. The TrA1331W modification construct pNJOC577 has hph and HSV-1 tk cassettes flanked by direct repeats, facilitating the generation of spontaneous loops and clean TrA1331W modifications from the hph and HSV-1 tk cassettes via homologous recombination between the two repeats. Spores from transformants with precise integration of the TrA1331W modification cassette were cultured using H. 2The isolates were collected in 0 and the dilutions were spread onto TrMM plates containing 1.5 μM 5-fluoro-2'-deoxyuridine (FdU) and incubated at 30 °C for 5 days to facilitate the identification of isolates that had lost the hph and HSV-1 tk cassettes. FdU-resistant isolates were then transferred to PDA plates and the absence of the hph and HSV-1 tk cassettes was verified by spore PCR. In this spore PCR, three primers were added: one primer annealing to the upstream region of the hph and tk cassettes, one primer annealing to the external region of the 3' integration site, and one primer annealing to the internal region of the hph and tk cassettes. The primers were designed to generate short or long PCR products depending on whether the hph and tk cassettes were still present or not. Single spore isolation was then performed on PDA + 1M sucrose plates for transformants that had lost the hph and tk cassettes. The plates were incubated at 30 °C for 3 to 5 days. Spores from each colony were transferred to a new PDA plate and the plate was incubated at 30°C for 5-7 days. To confirm the presence of the desired mutation in the TrA1331W gene, genomic DNA was prepared for several isolates, used to generate paired-end sequencing libraries, and sequenced using 2x150bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.) as described in Example 2. Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module. Reads were mapped to a model of the TrA1331W gene (SEQ ID NO:1) using the Map Read to Reference module with high stringency settings. The presence of the desired mutation was verified using the Basic Variant Detection module. One of the isolates with the desired mutation was named NJOC586 and kept for further testing.

[0117] Example 5: Transformation of Trichoderma reesei strain frt4new-1940-1996-2012-12-1 with pNJOC383 Trichoderma reesei frt4new-1940-1996-2012-12-1 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pNJOC383 (a plasmid carrying an Acremonium alcalophilum CBS114.92 lysozyme expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 14 and FIG. 2) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34°C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30°C for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18) using Map Read against the reference module at high stringency settings. One of the isolates with correct integration at all four sites was named NJOC587 and kept for further testing.

[0118] Example 6: Transformation of Trichoderma reesei TrA1331W modified strain (NJOC586) with pNJOC383 Trichoderma reesei NJOC586 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pNJOC383 (SEQ ID NO: 14; FIG. 2) was added to 100 μl of protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction was mixed, and incubated at 34°C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. Plates were incubated at 30°C for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred to new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Several transformants were then subjected to single spore isolation on PDA+1M sucrose plates. Plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 and plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2 and used to create paired end sequencing libraries and sequenced using 2x150bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module. Using Map Read against the reference module at high stringency settings, the reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18). One of the isolates with correct integration at all four sites was named NJOC588 and kept for further testing.

[0119] Example 7: Lysozyme activity assay (LSU(F) / ml) The whole broth from the fermentation was mixed in a rotisserie mixer at 30°C for approximately 2 hours. After mixing of the whole broth, all samples were diluted 100-fold with pre-dilution buffer and then mixed again using the rotisserie mixer for approximately 2 hours. The 100-fold pre-diluted samples were then diluted 10,000-fold with 0.1 M Tris-HCl, 0.1 M NaCl, 0.01% Triton X100 buffer, pH 7.5 (sample buffer) by 10-fold serial dilutions, followed by 3-fold serial dilutions down to 1 / 9 of the diluted samples. This method was used with a Beckman Coulter Biomek FX and SpectraMax plate reader (Molecular Devices). Lysozyme standards were diluted in sample buffer from a concentration of 0.05 LSU(F) / ml to a concentration of 0.002 LSU(F) / ml. A total of 50 μl of each dilution including the standard was transferred to a 96-well flat-bottom plate. 50 μL of 25ug / ml fluorescein-conjugated cell wall substrate solution was added to each well and then incubated at ambient temperature for 45 minutes. During incubation, reaction kinetics were monitored at 485nm (excitation) / 528nm (emission) in a 96-well plate at 15 minute intervals. Sample concentrations were determined by extrapolation from the generated calibration curve.

[0120] Example 8: Laboratory-scale fermentation showed that modification of the protein encoded by TrA1331W resulted in increased productivity / yield of lysozyme Strains NJOC587 and NJOC588 expressing four copies of lysozyme were evaluated in 2-liter fermentations. Each strain was grown on two PDA plates at 30°C for 5-7 days. Three 500 ml shake flasks, each containing 100 ml of shake flask medium, were inoculated with two plugs per shake flask from the PDA plates. The shake flasks were incubated at 28°C on an orbital shaker at 200 rpm for 48 hours. The cultures were used as seeds for the fermentation.

[0121] A total of 150 ml of each seed culture was used to inoculate a 3 liter glass jacketed fermenter (Applikon Biotechnology) containing 1.5 liters of fermentation batch medium. The fermenter was maintained at a temperature of 28°C and the pH was controlled at a set point of 3.5 + / - 0.1 using an Applikon 1030 control system. Air was added to the vessel at a rate of 2.5 L / min and the culture was agitated by a Rushton impeller rotating at 300-1100 rpm. Fermentation feed medium consisting of autoclaved glucose and phosphate was dosed at a rate of 0-14 g / L / h over a period of approximately 7 days. Aliquots of the total culture were taken on the 5th, 6th and 7th days and stored at 5-10°C before being processed in the lysozyme activity assay.

[0122] Lysozyme expression levels were measured as described in Example 7. Increased lysozyme expression was observed in the NJOC588 strain compared to NJOC587, indicating that the modification of the TrA1331W gene encoding a putative native steroid dehydrogenase is favorable for lysozyme expression.

[0123] Example 9: Identification of homologues of the TrA1331W encoded protein (SEQ ID NO:3) The amino acid sequence of the protein encoded by TrA1331W (SEQ ID NO: 3) was used to perform a BLAST search (E-value: 1.00e-5 and word length: 5) for homologues of proteins encoded by genes in the genomes of Aspergillus niger, Aspergillus oryzae and Fusarium venenatum. The single BLAST hits obtained for each organism are presented in Table 1:

[0124] [Table 1]

[0125] The percent identity between the different proteins was calculated using the Needleman-Wunsch algorithm as described above. The identities between the proteins are summarized in Table 2.

[0126] [Table 2]

[0127] According to Table 2, the proteins share significant sequence identity ranging from about 39% to about 70% identity (not surprisingly, the highest percent identity is found between the more closely related A. niger and A. oryzae proteins).

[0128] To further explore the relatedness between the proteins, the proteins were aligned using the MUSCLE algorithm version 3.8.31 with default parameters (Edgar, RC (2004). Nucleic Acids Research, 32(5), 1792-1797). The results from this multiple sequence alignment are shown in Figure 3. The proteins shared significant amino acid sequence identity as shown in Figure 3 where several stretches / blocks of highly conserved amino acid motifs, e.g., YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT motifs are shown. Taken together, the results indicate that the putative enzymes are likely to perform similar functions in different fungal hosts.

[0129] Example 10: Construction of a plasmid (pNJOC569; SEQ ID NO:27) for the deletion of the TrA1331W gene (SEQ ID NO:1) encoding a putative steroid dehydrogenase A plasmid for deletion of the entire protein encoded by TrA1331W (SEQ ID NO:1) was constructed by cloning the 5' targeting region, the hph (hygromycin phosphotransferase) and tk (HSV-1 thymidine kinase) cassettes, the repeats to be used for excision of the hph and tk cassettes, and the 3' targeting region into pUC19 (linearized with HindIII and SacI) using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England Biolabs®, Inc.). The 5' targeting region, the hph and tk cassettes, the repeats for excision of the hph and tk cassettes, and the 3' targeting region were cloned into pUC19 (linearized with HindIII and SacI) using the primer set: oNJ587 (SEQ ID NO: 19) + oNJ588 (SEQ ID NO: 28), oNJ595 (SEQ ID NO: 29) + oNJ596 (SEQ ID NO: 30), oNJ592 (SEQ ID NO: 31) + oNJ593 (SEQ ID NO: 32), and oNJ589 (SEQ ID NO: 33) + oNJ590 (SEQ ID NO: 34) was used for PCR amplification.

[0130] Amplification reactions were carried out using Phusion® Hot Start II DNA polymerase (Thermo Fisher Scientific) according to the manufacturer's instructions. PCR consisted of 5 ng of pJfyS1579-41-11 (WO 2010 / 039840) (template for the hph / tk cassette) or 50 ng of BTR213 genomic DNA (WO 2013 / 086633) as template, 1× HF buffer, 200 μM of each dNTP, 500 nM of forward primer, 500 nM of reverse primer, 1 unit of Phusion® Hot Start II DNA polymerase and sterile Milli-Q® H 2O was added to a final volume of 50 μl. The reactions were incubated in a Bio-Rad C1000 Touch™ thermal cycler (Bio-Rad Laboratories) programmed for 1 cycle at 98° C. for 3 min; 35 cycles each of 98° C. for 10 s, 65° C. for 30 s, and 72° C. for 30 s (repeat fragments) or 2.5 min; and 1 cycle at 72° C. for 5 min. After thermocycling, the PCR products were separated by 1% agarose gel electrophoresis in TBE buffer, and bands corresponding to the different PCR products (1587 bp, 4405 bp, 354 bp, and 1571 bp) were excised from the gel and purified using NucleoSpin® Gel and PCR clean-up kit (Macherey-Nagel) according to the manufacturer's instructions. pUC19 was diluted with 5 μg of pUC19, 20 units each of HindIII-HF (New England Biolabs®, Inc.) and SacI-HF (New England Biolabs®, Inc.), 1× CutSmart® buffer (New England Biolabs®, Inc.) and sterile Milli-Q® H 2The pUC19 HindIII / SacI fragment was digested with HindIII and SacI in a 50 μl reaction consisting of 0 and a final volume of 50 μl. The reaction was incubated at 37° C. and then subjected to 1% agarose gel electrophoresis in TBE buffer. The 2645 bp pUC19 HindIII / SacI fragment was excised from the gel and purified using NucleoSpin® Gel and PCR Cleanup Kit (Macherey-Nagel) according to the manufacturer's instructions. The PCR product and the pUC19 HindIII / SacI fragment were fused together using a NEBuilder® HiFi DNA Assembly Master Mix kit (New England Biolabs) in a total volume of 30 μL consisting of 1× NEBuilder® HiFi Assembly Master Mix and 0.04 pmoles of PCR product each. The reaction was incubated at 50° C. for 45 minutes and then placed on ice. One μL of the reaction was used to transform 60 μL of Stellar™ competent cells (Clontech Laboratories, Inc.) according to the manufacturer's instructions. The transformation reaction was spread onto two 2xYT+Amp plates and incubated overnight at 37° C. Putative transformant colonies were isolated from the selection plates and plasmid DNA was prepared from each using a QIAprep Spin Miniprep kit (Qiagen) and screened for proper insertion of the fragment by digestion with PvuII. Plasmid DNA that gave the expected band pattern upon restriction enzyme digestion (4224 bp, 3117 bp, 2364 bp, 370 bp, 296 bp) was used to generate paired-end sequencing libraries and sequenced using 2×150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module. Reads were mapped to a model of the pNJOC569 plasmid (SEQ ID NO: 27) using Map Read against a reference module with high stringency settings.The Basic Variant Detection module was used to detect the presence of any single nucleotide polymorphisms.The plasmid with the predicted nucleotide sequence was named pNJOC569 (Figure 4).

[0131] Example 11: Construction of a Trichoderma reesei strain with a deletion of the TrA1331W gene encoding a putative steroid dehydrogenase (NJOC584-5D8A) Trichoderma reesei frt4new-1940-1996-2012-12-1 protoplasts were generated as described in Example 2. Approximately 2-4 μg of the linearized TrA1331W deletion cassette from pNJOC569 (7716 bp PmeI fragment) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, and the reaction was mixed and incubated at 34 °C for 30 min. STC (1 ml) was then added, and the contents were spread onto PDA + 1M sucrose plates and incubated overnight at 30 °C. The next day, an overlay consisting of PDA + hygromycin B was added to a final concentration of 10 μg / ml hygromycin B, and the plates were incubated at 30 °C for 5-7 days. Hygromycin-resistant transformants were then transferred to PDA plates and incubated at 30 °C for 5-7 days. Transformants were screened for correct integration of the TrA1331 deletion cassette by spore PCR. For each transformant, spores were collected using a sterile 1 μl inoculation loop and suspended in 20 μl of dilution buffer (PHIRE™ Plant Direct PCR Kit, Thermo Scientific) in a thin-walled PCR tube. Each spore suspension was used as a template in a PCR reaction to screen for integration of the TrA1331W deletion cassette at the TrA1331W locus. Two PCRs were performed for each transformant; one for the 5′ site of integration and one for the 3′ site of integration. Screening for 5′ integration was performed using a primer (oNJ632, SEQ ID NO: 35) that anneals to the upstream region of the integration site and a primer (AgJg685, SEQ ID NO: 36) that anneals to a region inside the hph and tk cassettes. Screening for 3' integration was performed using a primer (oNJ633, SEQ ID NO: 37) that anneals to a region downstream of the integration site and a primer (AgJg604, SEQ ID NO: 38) that anneals to a region internal to the hph and tk cassettes.Each PCR reaction contained 1 μl of spore suspension, 10 pmoles of each primer, 10 μl of 2x PHIRE™ Plant PCR Buffer (PHIRE™ Plant Direct PCR Kit, Thermo Scientific), 0.4 μl of PHIRE™ Hot Start II DNA Polymerase (PHIRE™ Plant Direct PCR Kit, Thermo Scientific) and H. 2 The PCR products were analyzed by 1% agarose gel electrophoresis using TBE buffer to a final volume of 20 μl. Thermocycling was performed according to the manufacturer's instructions. PCR products were analyzed by 1% agarose gel electrophoresis using TBE buffer. Transformants yielding the desired PCR product were then subjected to single spore isolation on PDA+1M sucrose plates. Plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to a new PDA plate and plates were incubated at 30°C for 5-7 days. The above 5' and 3' integration verification PCR was repeated and PCR products were analyzed by 1% agarose gel electrophoresis using TBE buffer. The TrA1331W deletion construct from pNJOC569 has the hph and HSV-1 tk cassettes flanked by direct repeats, facilitating the generation of spontaneous loops from the hph and HSV-1 tk cassettes and clean TrA1331W deletion via homologous recombination between the two repeats. Spores from transformants with precise integration of the TrA1331W modification cassette were cultured using H. 2The isolates were collected in 0 and the dilutions were spread onto TrMM plates containing 1.5 μM 5-fluoro-2'-deoxyuridine (FdU) and incubated at 30 °C for 5 days to facilitate the identification of isolates that had lost the hph and HSV-1 tk cassettes. FdU-resistant isolates were then transferred to PDA plates and the absence of the hph and HSV-1 tk cassettes was verified by spore PCR. In this spore PCR, three primers were added: one primer annealing to the upstream region of the hph and tk cassettes, one primer annealing to the external region of the 3' integration site, and one primer annealing to the internal region of the hph and tk cassettes. The primers were designed to generate short or long PCR products depending on whether the hph and tk cassettes were still present or not. Single spore isolation was then performed on PDA + 1M sucrose plates for transformants that had lost the hph and tk cassettes. The plates were incubated at 30 °C for 3 to 5 days. Spores from each colony were transferred to a new PDA plate and the plate was incubated at 30°C for 5-7 days. To confirm the presence of the desired deletion in the TrA1331W gene, genomic DNA was prepared for several isolates, used to generate paired-end sequencing libraries, and sequenced using 2x150bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.) as described in Example 2. Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module. Reads were mapped to a model of the TrA1331W gene (SEQ ID NO:1) using the Map Read to Reference module with high stringency settings. The presence of the desired deletion was verified by the InDel and Structural Variant modules. One of the isolates with the desired deletion was named NJOC584-5D8A and kept for further testing.

[0132] Example 12: Transformation of Trichoderma reesei strain NJOC584-5D8A with pNJOC383 Trichoderma reesei NJOC584-5D8A protoplasts were generated as described in Example 2. Approximately 1-10 μg of pNJOC383 (SEQ ID NO: 14 and FIG. 2) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction was mixed, and incubated at 34°C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30°C for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred to new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Several transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2 and used to create paired end sequencing libraries and sequenced using 2x150bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module. Reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18) using Map Read against the reference module at high stringency settings. One of the isolates with correct integration at all four sites was named NJOC618-81D and kept for further testing.

[0133] Example 13: Laboratory-scale fermentation showed that deletion of the protein encoded by TrA1331W also resulted in increased productivity / yield of lysozyme Strains NJOC587 (control) and NJOC618-81D expressing four copies of lysozyme were evaluated in 2-liter fermentations. Each strain was grown on two PDA plates at 30°C for 5-7 days. Three 500 ml shake flasks, each containing 100 ml of shake flask medium, were inoculated with two plugs per shake flask from the PDA plates. The shake flasks were incubated at 28°C on an orbital shaker at 200 rpm for 48 hours. The cultures were used as seeds for the fermentation.

[0134] A total of 150 ml of each seed culture was used to inoculate a 3 liter glass jacketed fermenter (Applikon Biotechnology) containing 1.5 liters of fermentation batch medium. The fermenter was maintained at a temperature of 28°C and the pH was controlled at a set point of 3.5 + / - 0.1 using an Applikon 1030 control system. Air was added to the vessel at a rate of 2.5 L / min and the culture was agitated by a Rushton impeller rotating at 300-1100 rpm. Fermentation feed medium consisting of autoclaved glucose and phosphate was dosed at a rate of 0-14 g / L / h over a period of approximately 7 days. Aliquots of the total culture were taken on the 5th, 6th and 7th days and stored at 5-10°C before being processed in the lysozyme activity assay.

[0135] Lysozyme expression levels were measured as described in Example 7. Increased lysozyme expression was observed in the steroid dehydrogenase deletion strain NJOC618-81D compared to NJOC587 at all time points assayed (Figure 5). Results showed that inactivation of the TrA1331W gene, which encodes a putative native steroid dehydrogenase, favored lysozyme expression.

[0136] Example 14: Transformation of Trichoderma reesei strain frt4new-1940-1996-2012-12-1 with pTmmD-Tl_lipase Trichoderma reesei frt4new-1940-1996-2012-12-1 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pTmmD-Tl_lipase (Thermomyces lanuginosus HL703 lipase variant expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 39 and FIG. 6) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34° C. for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30°C for 7–9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5–7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5–7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3–5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5–7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18) using Map Read against the reference module at high stringency settings. One of the isolates with correct integration at all four sites was named NJOC600-2A and kept for further testing.

[0137] Example 15: Transformation of Trichoderma reesei strain NJOC586 with pTmmD-Tl_lipase Trichoderma reesei NJOC586 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pTmmD-Tl_lipase (Thermomyces lanuginosus HL703 lipase variant expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 39 and FIG. 6) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34° C. for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30° C. for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18) using Map Read against the reference module at high stringency settings. One of the isolates with correct integration at all four sites was named NJOC609-1A and kept for further testing.

[0138] Example 16: Activity assay of lipase LU(LXP) / ml This method was used in conjunction with a Beckman Coulter Biomek FX and SpectraMax plate reader (Molecular Devices).

[0139] The culture supernatant was diluted with 0.05 M MOPS (3-(N-morpholino)propanesulfonic acid), 10 mM CaCl 2 , appropriate dilutions were made in 0.01% TritonX100 buffer, pH 7.5 (sample buffer), followed by serial dilutions ranging from 0 to 1 / 3 to 1 / 9 of the diluted sample. Lipex standards were diluted in sample buffer from a concentration of 4.0 LU(LXP) / ml to a concentration of 0.197 LU(LXP) / ml. Each dilution containing a total of 20 μl of standard was transferred to a 96-well flat-bottom plate. pNP-palmitate substrate solution (pNPP stock was 7.8 mM pNP-palmitate in 9.99% EtOH - working solution per liter was 500 ml 0.1 M MOPS, pH 7.5, 20 ml pNPP stock, 100 ml 10% TritonX100, 14.7 ml 680 mM CaCl 2 and H 2 200 μL of 100% PBS (made up to volume with O) was added to each well and then incubated for 30 minutes at ambient temperature. During incubation, reaction rates were measured at optical density at 405 nm in 96-well plates over a 20-minute period. Sample concentrations were determined by extrapolation from the constructed calibration curve.

[0140] Example 17: Laboratory-scale fermentation showed that deletion of the protein encoded by TrA1331W also resulted in increased productivity / yield of lipase Strains NJOC600-2A (control) and NJOC609-1A expressing four copies of lysozyme were evaluated in 2-liter fermentations. Each strain was grown on two PDA plates at 30°C for 5-7 days. Three 500 ml shake flasks, each containing 100 ml of shake flask medium, were inoculated with two plugs per shake flask from the PDA plates. The shake flasks were incubated at 28°C on an orbital shaker at 200 rpm for 48 hours. The cultures were used as seeds for the fermentation.

[0141] A total of 150 ml of each seed culture was used to inoculate a 3 liter glass jacketed fermenter (Applikon Biotechnology) containing 1.5 liters of fermentation batch medium. The fermenter was maintained at a temperature of 28°C and the pH was controlled at a set point of 4.5 + / - 0.1 using an Applikon 1030 control system. Air was added to the vessel at a rate of 2.5 L / min and the culture was agitated by a Rushton impeller rotating at 300-1100 rpm. Fermentation feed medium consisting of autoclaved glucose and phosphate was dosed at a rate of 0-15 g / L / h over a period of approximately 5 days. Samples (supernatants) were collected on days 2, 3, 4 and 5 and stored at 5°C before being processed in the lipase activity assay.

[0142] Lipase expression levels were measured as described in Example 16. Increased lipase expression was observed in the steroid dehydrogenase deletion strain NJOC609-1A compared to the NJOC600-2A control at all time points assayed (Figure 7) (improvements ranging between 45% and 132%). Results showed that inactivation of the TrA1331W gene encoding a putative native steroid dehydrogenase was favorable for lipase expression.

[0143] Example 18: Transformation of Trichoderma reesei strain frt4new-1940-1996-2012-12-1 with pSMai326 Trichoderma reesei frt4new-1940-1996-2012-12-1 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pSMai326 (a plasmid carrying a Paenibacillus sp. xanthanase variant expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 40 and FIG. 8) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction was mixed, and incubated at 34°C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30°C for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18) using Map Read against the reference module at high stringency settings. One of the isolates with correct integration at all four sites was named NJOC608-1B and was kept for further testing.

[0144] Example 19: Transformation of Trichoderma reesei strain NJOC586 with pSMai326 Trichoderma reesei NJOC586 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pSMai326 (a plasmid carrying a Paenibacillus sp. xanthanase variant expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 40 and FIG. 8) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34°C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30°C for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18) using Map Read against the reference module at high stringency settings. One of the isolates with correct integration at all four sites was named NJOC617-77C and was kept for further testing.

[0145] Example 20: Xanthanase XGU(A) Activity Assay The method was performed on a Thermo Arena 30 analyzer. Samples were prepared in 0.1 M ACES (N-(2-acetamido)-2-aminoethanesulfonic acid), 0.056 M NaOH, 4 mM CaCl 2 2H 2 Appropriate dilutions were made with 0.025% Brij® L23 pH 7 buffer (dilution buffer). Dilutions were made into xanthanase standards and a 7-point curve was generated using dilution buffer. 20 μL of each sample and standard was added to 125 μL of 0.1 M ACES, 0.056 M NaOH (assay buffer) and 50 μL of substrate (0.1% (w / v) modified xanthan gum, 0.48% (v / v) ethanol, 0.1 M ACES, 0.06 M NaOH) and incubated at 50° C. for 1200 seconds. 100 μL of stopper (50 g / L potassium sodium tartrate, 20 g / L PAHBAH (4-hydroxybenzhydrazide), 5.52 g / L bismuth(III) acetate, 0.5 M NaOH) was added to each reaction and incubated at 50° C. for 1200 seconds. Endpoint measurements were taken at 405 nm. Sample activity was determined by extrapolation from a constructed standard curve.

[0146] Example 21: Laboratory-scale fermentation showed that deletion of the protein encoded by TrA1331W also resulted in increased productivity / yield of xanthanase Strains NJOC608-1B (control) and NJOC617-77C expressing four copies of lysozyme were evaluated in 2-liter fermentations. Each strain was grown on two PDA plates at 30°C for 5-7 days. Three 500 ml shake flasks, each containing 100 ml of shake flask medium, were inoculated with two plugs per shake flask from the PDA plates. The shake flasks were incubated at 28°C on an orbital shaker at 200 rpm for 48 hours. The cultures were used as seeds for the fermentation.

[0147] A total of 150 ml of each seed culture was used to inoculate a 3 liter glass jacketed fermenter (Applikon Biotechnology) containing 1.5 liters of fermentation batch medium. The fermenter was maintained at a temperature of 28°C and the pH was controlled at a set point of 4.5 + / - 0.1 using an Applikon 1030 control system. Air was added to the vessel at a rate of 2.5 L / min and the culture was agitated by a Rushton impeller rotating at 300-1100 rpm. Fermentation feed medium consisting of autoclaved glucose and phosphate was dosed at a rate of 0-15 g / L / h over a period of approximately 7 days. Samples (supernatants) were collected on days 2-7 and stored at 5°C before being processed in the xanthanase activity assay.

[0148] Lipase expression levels were measured as described in Example 20. Increased xanthanase expression was observed in the steroid dehydrogenase deletion strain NJOC617-77C compared to the NJOC608-1B control at all time points assayed (Figure 9) (7-28% improvement). Results showed that inactivation of the TrA1331W gene, encoding a putative native steroid dehydrogenase, was favorable for xanthanase expression.

[0149] Example 22: Transformation of Trichoderma reesei strain frt4new-1940-1996-2012-12-1 with pTmmD-Mf_lysozyme Trichoderma reesei frt4new-1940-1996-2012-12-1 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pTmmD-Mf_lysozyme (a plasmid carrying a Myceliophthora fergusii lysozyme expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 41 and FIG. 10) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34°C for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30°C for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred to COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Using Map Read against the reference module at high stringency settings, the reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18). One of the isolates with correct integration at all four sites was named NJOC601-5A and kept for further testing.

[0150] Example 23: Transformation of Trichoderma reesei strain NJOC586 with pTmmD-Mf_lysozyme Trichoderma reesei NJOC586 protoplasts were generated as described in Example 2. Approximately 1-10 μg of pTmmD-Mf_lysozyme (a plasmid carrying a Myceliophthora fergusii lysozyme expression cassette flanked by FRT-F and FRT-F3 sites for FLP-mediated integration at four loci with FRT-F and FRT-F3 sites in the host strain; SEQ ID NO: 41 and FIG. 10) was added to 100 μl of the protoplast solution and mixed gently. PEG buffer (250 μl) was added, the reaction mixed, and incubated at 34° C. for 30 min. STC (1 ml) was then added, and the contents were spread onto COVE plates for selection of amdS. The plates were incubated at 30° C. for 7-9 days. Spores from transformants from each COVE plate were transferred onto COVE2 glucose plates containing 75 μg / ml 5-fluorocytosine (5-FC) (Sigma Chemical Co.) and incubated at 30°C for 5-7 days. Spores from transformants on COVE2 glucose plates containing 5-FC were transferred onto new COVE2 glucose plates containing 5-FC and incubated at 30°C for 5-7 days. Some transformants were then subjected to single spore isolation on PDA+1M sucrose plates. The plates were incubated at 30°C for 3-5 days. Spores from each colony were transferred onto COVE2 plates and the plates were incubated at 30°C for 5-7 days. To confirm integration of the lysozyme expression cassette from pNJOC383 at the cbh1, cbh2, eg1 and xyn2 loci, genomic DNA was prepared in several single spore isolates as described in Example 2, used to generate paired-end sequencing libraries and sequenced using 2 x 150 bp chemistry on a NEXTSEQ™ 500 system (Illumina Inc.). Sequence analysis was performed using CLC Genomics Workbench version 11.0.1 (QIAGEN). Reads were trimmed using the Trim Reads module.Using Map Read against the reference module at high stringency settings, the reads were mapped to models of the cbh1, cbh2, eg1 and xyn2 loci (SEQ ID NOs: 15-18). One of the isolates with correct integration at all four sites was named NJOC610-2B and was kept for further testing.

[0151] Example 24: Lysozyme LSU(A) Activity Assay This method was used with a Beckman Coulter Biomek FX and SpectraMax plate reader (Molecular Devices). Whole culture samples were appropriately diluted in 0.1 M acetate, 50 mM NaCl, 0.01% TritonX100 buffer, pH 4.5 (sample buffer), followed by serial dilutions ranging from 0 to 1 / 3 to 1 / 9 of the diluted sample. Lysozyme standards were diluted in sample buffer from a concentration of 50 LSU(A) / ml to a concentration of 2.469 LSU(A) / ml. Each dilution, including a total of 20 μl of standard, was transferred to a 96-well flat-bottom plate. 200 μl of 0.26 g / L Micrococcus lysodeikticus substrate solution was added to each well, which was then incubated for 75 min at ambient temperature. At the completion of the incubation, an optical density of 450 nm was obtained in the 96-well plate. Sample concentrations were determined by extrapolation from a constructed calibration curve.

[0152] Example 25: Laboratory-scale fermentation showed that deletion of the protein encoded by TrA1331W also resulted in increased productivity / yield of Mf lysozyme Strains NJOC601-5A (control) and NJOC610-2B expressing four copies of lysozyme were evaluated in 2-liter fermentations. Each strain was grown on two PDA plates at 30°C for 5-7 days. Three 500 ml shake flasks, each containing 100 ml of shake flask medium, were inoculated with two plugs per shake flask from the PDA plates. The shake flasks were incubated at 28°C on an orbital shaker at 200 rpm for 48 hours. The cultures were used as seeds for the fermentation.

[0153] A total of 150 ml of each seed culture was used to inoculate a 3 liter glass jacketed fermenter (Applikon Biotechnology) containing 1.5 liters of fermentation batch medium. The fermenter was maintained at a temperature of 28°C and the pH was controlled at a set point of 3.5 + / - 0.1 using an Applikon 1030 control system. Air was added to the vessel at a rate of 2.5 L / min and the culture was agitated by a Rushton impeller rotating at 300-1100 rpm. Fermentation feed medium consisting of autoclaved glucose and phosphate was dosed at a rate of 0-15 g / L / h over a period of approximately 7 days. Aliquots of the total culture were taken on days 4, 5, 6 and 7 and stored at 5°C-10°C before being subjected to processing in a lysozyme activity (LSU(A)) assay.

[0154] Lipase expression levels were measured as described in Example 24. Increased Mf lysozyme expression was observed in the steroid dehydrogenase deletion strain NJOC610-2B compared to the NJOC601-5A control at all time points assayed (Figure 11) (6-47% improvement). Results showed that inactivation of the TrA1331W gene encoding a putative native steroid dehydrogenase was favorable for Mf lysozyme expression.

[0155] Example (Aspergillus niger) Materials and Methods Unless otherwise specified, DNA manipulations and transformations were performed using standard techniques of molecular biology, such as those described in Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, FM et al. (eds.) "Current protocols in Molecular Biology", John Wiley and Sons, 1995; Harwood, CR, and Cutting, SM (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990.

[0156] Purchased materials (E. coli and kits) E. coli DH5α (Toyobo) was used for plasmid construction and amplification. Amplified plasmids were recovered using a Qiagen Plasmid Kit (Qiagen). Ligation was performed using a DNA Ligation Kit (Takara) or T4 DNA Ligase (Boehringer Mannheim). Polymerase chain reaction (PCR) was performed using the Expanded™ PCR system (Boehringer Mannheim). A QIAquick™ Gel Extraction Kit (Qiagen) was used for purification of PCR fragments and extraction of DNA fragments from agarose gels.

[0157] enzyme Enzymes for DNA manipulation (eg, restriction endonucleases, ligases, etc.) were available from New England Biolabs, Inc. and used according to the manufacturer's instructions.

[0158] Plasmids pBluescript II SK-(Stratagene#212206) pHUda963, a derivative of pHUda801 (WO 2012 / 160093), harboring the A. nidulans pyrG gene and the herpes simplex virus (HSV) thymidine kinase gene (TK) driven by the A. nidulans glyceraldehyde-3-phosphate dehydrogenase promoter (Pgpd) and the A. nidulans tryptophan synthase terminator (TtrpC), is described in Example 4 of WO 2012 / 160093.

[0159] pJaL1470, harboring the Acremonium alcalophilus lysozyme (Aa lysozyme) gene, is described in WO2015144936A1.

[0160] microbial strains The expression host strains Aspergillus niger C5553 and M1816 (pyrG- phenotype / uridine auxotrophy for C5553) were isolated by Novozymes and are derivatives of Aspergillus niger NN049184 isolated from soil as described in Example 14 of WO 2012 / 160093. C5553 and M1816 have been genetically engineered to disrupt expression of amyloglycosidase activity.

[0161] Culture medium The COVE trace metals solution contains 0.04 g of NaB 4 O 7 10H 2 0, 0.4 g CuSO 4 5H 2 o, 1.2 g FeSO 4 7H 2 0, 0.7 g MnSO 4 H 2 O, 0.8 g Na 2 MoO2 2H 2 0, 10 g ZnSO 4 7H 2 0, and deionized water to 1 liter.

[0162] 50x COVE salt solution is 26 g KCl, 26 g MgSO 4 7H 2 O, 76g KH 2 PO 4 , 50 ml of COVE trace metals solution, and deionized water to 1 liter.

[0163] COVE medium contains 342.3 g sucrose, 20 ml 50x COVE salt solution, 10 ml 1 M acetamide, 10 ml 1.5 M CsCl 2 , 25 g of Noble agar, and deionized water to 1 liter.

[0164] COVE-N-Gly plates contain 218 g sorbitol, 10 g glycerol, and 2.02 g KNO 3 , 50 ml of Cove salts solution, 25 g of Noble agar, and deionized water, made up to 1 liter.

[0165] COVE-N(tf) is 342.3 g sucrose, 3 g NaNO 3 , 20 ml of Cove salts solution, 30 g of Noble agar, and deionized water, made up to 1 liter.

[0166] COVE-N top layer agarose is 342.3 g sucrose, 3 g NaNO 3 , 20 ml of Cove salts solution, 10 g of low melt agarose, and deionized water to 1 liter.

[0167] COVE-N is a mixture of 30g sucrose, 3g NaNO 3 , 20 ml of Cove salts solution, 30 g of Noble agar, and deionized water, made up to 1 liter.

[0168] STC buffer contains 0.8 M sorbitol, 25 mM Tris, pH 8, and 25 mM CaCl 2 It became.

[0169] STPC buffer consisted of 40% PEG4000 in STC buffer.

[0170] LB medium consisted of 10 g tryptone, 5 g yeast extract, 5 g sodium chloride, and deionized water up to 1 liter.

[0171] LB plus ampicillin plates were composed of 10 g tryptone, 5 g yeast extract, 5 g sodium chloride, 15 g Bacto agar, 100 μg ampicillin per ml, and deionized water up to 1 liter.

[0172] YPG medium consisted of 10 g yeast extract, 20 g Bacto peptone, 20 g glucose, and deionized water up to 1 liter.

[0173] SOC medium consisted of 20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 10 ml of 250 mM KCl, and deionized water up to 1 liter.

[0174] The TAE buffer consisted of 4.84 g Tris base, 1.14 ml glacial acetic acid, 2 ml 0.5 M EDTA pH 8.0, and deionized water up to 1 liter.

[0175] Transformation of Aspergillus Transformation of Aspergillus species can be accomplished using standard methods for yeast transformation. A preferred procedure in the present invention is as follows.

[0176] 100 ml of YPG medium supplemented with 10 mM uridine was inoculated with the Aspergillus niger host strain and incubated at 32 °C and 80 rpm for 16 h. The pellet was collected, washed with 0.6 M KCl, and then resuspended in 20 ml of 0.6 M KCl containing a commercial β-glucanase product (GLUCANEX™, Novozymes A / S, Bagsvaerd, Denmark) at a final concentration of 20 mg per ml. The suspension was incubated at 32 °C and 80 rpm until protoplasts were formed and subsequently washed twice with STC buffer.

[0177] Protoplasts were counted with a hematometer and then resuspended in an 8:2:0.1 solution of STC:STPC:DMSO to a final concentration of 2.5 × 10 7 The reaction mixture was adjusted to 100 μl of protoplasts / ml. Approximately 4 μg of plasmid DNA was added to 100 μl of the protoplast suspension, mixed gently and then incubated on ice for 30 min. 1 ml of SPTC was added and the protoplast suspension was incubated at 37° C. for 20 min. After addition of 10 ml of 50° C. Cove or Cove-N top agarose, the reaction was poured onto Cove or Cove-N(tf) agar plates and the plates were incubated at 30° C. for 5 days.

[0178] [Table 3]

[0179] 3-step cycle: 1. Pre-denaturation: 94℃, 2 minutes 2. Denaturation: 94℃, 15 seconds 3. Annealing: Tm-[5~10]℃ * , 30 seconds 4.Elongation: 68℃, 1 min / kb 5. Repeat steps #2-4 for a total of 35 cycles

[0180] Laboratory-scale tank culture for the production of Aa lysozyme. The fermentation was carried out as fed-batch fermentation (H. Pedersen 2000, Appl Microbiol Biotechnol, 53:272-277). The selected strains were pre-cultured in liquid medium, and then the grown mycelium was transferred to a tank for further cultivation for enzyme production. The culture was carried out for 8 days at 34°C and pH 4.75 with a non-excessive supply of glucose and ammonium to inhibit enzyme production. The culture was used for enzyme assay.

[0181] array SEQ ID NO: 4: Aspergillus niger steroid dehydrogenase genomic DNA sequence SEQ ID NO:5: Aspergillus niger steroid dehydrogenase coding sequence (or cDNA) SEQ ID NO:6: Aspergillus niger steroid dehydrogenase amino acid sequence

[0182] Example 26 Disruption of the steroid dehydrogenase gene in Aspergillus niger Construction of the steroid dehydrogenase gene disruption plasmid pIhar473 Plasmid pIhar473 was constructed to carry the 5' and 3' flanking regions of the Aspergillus niger steroid dehydrogenase gene and the human herpes simplex virus 1 (HSV-1) thymidine kinase gene, separated by the A. nidulans orotidine-5'-phosphate decarboxylase gene (pyrG) and its terminator repeat as selectable markers. The HSV-1 thymidine kinase gene is located 3' to the 3' flanking region of the steroid dehydrogenase gene, allowing for counterselection of Aspergillus niger transformants that do not target the steroid dehydrogenase gene locus precisely. The plasmid was constructed in several steps as described below.

[0183] A PCR product with the 3' flanking region of A. niger steroid dehydrogenase was generated using the following primers: SEQ ID NO: 42: Primer IH1232-3'steD-F: 5'-aactctctcctctagaTTATGTAGCATGAGACCAGCGGGGA-3' SEQ ID NO: 43: Primer IH1233-3'steD-R: 5'-acaggagaattcttaattaaAGTCCGGGGTGGGAGTTTTCAGGC-3' It was made using.

[0184] The desired fragment was amplified by PCR in reactions consisting of approximately 100 ng of genomic DNA of Aspergillus niger NN049184 as described in Materials and Methods. Reactions were incubated in a Bio-Rad® C1000 Touch™ thermal cycler programmed for 1 cycle at 94°C for 2 min; 35 cycles each of 94°C for 15 s, 55°C for 30 s, and 68°C for 2 min; and a 4°C hold. The resulting 1,500 bp PCR fragment was purified by 0.8% agarose gel electrophoresis using TAE buffer, excised from the gel, and extracted using a QIAQUICK® Gel Extraction Kit.

[0185] Plasmid pHUda963 was digested with XbaI and PacI (New England Biolabs Inc.) and purified by 0.8% agarose gel electrophoresis using TAE buffer, where the 8,153 bp fragment was excised from the gel and extracted using a QIAQUICK® Gel Extraction Kit. The 8,153 bp fragment was ligated to the 1,500 bp PCR fragment using an In-Fusion kit (Clontech Laboratories, Inc.) according to the manufacturer's instructions. 1 μL of the reaction mixture was transformed into DH5α chemically competent E. coli cells. Transformants were spread on LB+ampicillin plates and incubated overnight at 37° C. Plasmid DNA was purified from several transformants using a QIA mini-prep kit. Plasmid DNA was screened for proper ligation by use of the appropriate restriction enzyme, followed by 0.8% agarose gel electrophoresis using TAE buffer. One plasmid was designated pIhar473-3'steD.

[0186] A PCR product with the 5' flanking region of A. niger steroid dehydrogenase was generated using the following primers: SEQ ID NO: 44: Primer IH1230-5'steD-F: 5'-gtggcggccgcgtttaaacATCCCTATTTTAAATACCGAGTATG-3' SEQ ID NO: 45: Primer IH1231-5'steD-R: 5'-tcagtcacccggatccctaATGGTGGCAGTCGTGTTGGATGCCT-3' It was made using.

[0187] The desired fragment was amplified by PCR in reactions consisting of approximately 100 ng of genomic DNA from Aspergillus niger NN049184 as described in Materials and Methods. Reactions were incubated in a Bio-Rad® C1000 Touch™ thermal cycler programmed for 1 cycle at 94°C for 2 min; 35 cycles each of 94°C for 15 s, 55°C for 30 s, and 68°C for 2 min; and a 4°C hold. The 1,500 bp PCR fragment was purified by 0.8% agarose gel electrophoresis using TAE buffer, excised from the gel, and extracted using a QIAQUICK® Gel Extraction Kit.

[0188] Plasmid pIhar473-3'steD was digested with PmeI and BamHI (New England Biolabs Inc.) and purified by 0.8% agarose gel electrophoresis using TAE buffer, where the 9,653 bp fragment was excised from the gel and extracted using a QIAQUICK® Gel Extraction Kit. The 9,653 bp fragment was ligated to the 1,500 bp PCR fragment using an In-Fusion kit (Clontech Laboratories, Inc.) according to the manufacturer's instructions. 5 μL of the ligation mixture was transformed into DH5α chemically competent E. coli cells. Transformants were spread on LB+ampicillin plates and incubated overnight at 37°C. Plasmid DNA was purified from several transformants using a QIA mini-prep kit. Plasmid DNA was screened for proper ligation by use of the appropriate restriction enzymes, followed by 0.8% agarose gel electrophoresis using TAE buffer. One plasmid was designated pIhar473 (SEQ ID NO: 46, Figure 12).

[0189] Disruption of the steroid dehydrogenase gene in Aspergillus niger strain M1816 Protoplasts of Aspergillus niger strain M1816 were prepared by culturing the strain in 100 ml of YPG medium supplemented with 10 mM uridine for 16 h at 32 °C with gentle agitation at 80 rpm. The pellet was collected, washed with 0.6 M KCl, and then resuspended in 20 ml of 0.6 M KCl containing a commercial β-glucanase product (GLUCANEX™, Novozymes A / S, Bagsvaerd, Denmark) at a final concentration of 20 mg per ml. The suspension was incubated at 32 °C and 80 rpm until protoplasts were formed. The protoplasts were filtered through a MIRACLOTH®-lined funnel into a 50 ml sterile plastic centrifuge tube, followed by washing with 0.6 M KCl to extract the trapped protoplasts. The combined filtrate and supernatant were collected by centrifugation at 2,000 rpm for 15 min. The supernatant was discarded and the pellet was washed with 10–25 ml of STC and centrifuged again at 2,000 rpm for 10 min, followed by two washes with STC buffer. Protoplasts were counted with a hematometer and then resuspended in an 8:2:0.1 solution of STC:STPC:DMSO to a final concentration of 2.5 × 10 7 The solution was adjusted to protoplasts / ml.

[0190] Approximately 4 μg of plhar473 was added to 1 ml of the protoplast suspension, mixed gently, and then incubated on ice for 30 min. 3 ml of SPTC was added and the protoplast suspension was incubated at 37°C for 20 min. After adding 12 ml of 50°C COVE-N top agarose, the mixture was poured onto COVE-N plates and these plates were incubated at 30°C for 7 days. The grown transformants were transferred with a sterile toothpick to COVE-N plates supplemented with 1.5 uM 5-fluoro-2-deoxyuridine (FdU), an agent that kills cells expressing the herpes simplex virus (HSV) thymidine kinase gene (TK) present in plhar473. Single spore isolates were transferred to COVE-N-gly plates.

[0191] Transformant candidates of Aspergillus niger strain M1816 containing plhar473, which disrupts the steroid dehydrogenase gene, were screened by Southern analysis. Each of the spore-purified transformants was cultured in 3 ml of YPG medium and incubated at 30°C for 2 days with shaking at 200 rpm. Biomass was harvested using a MIRACLOTH®-lined funnel. The crushed mycelium was subjected to genomic DNA preparation using the FastDNA SPIN Kit for Soil (MP Biomedicals) according to the manufacturer's instructions.

[0192] Southern blot analysis was performed to confirm the disruption of the steroid dehydrogenase locus. Five micrograms of genomic DNA from each transformant was digested with SpeI. The genomic DNA digestion reaction consisted of 5 μg of genomic DNA, 1 μl of SpeI, 2 μl of 10×NEB CutSmart buffer, and water up to 20 μl. The genomic DNA digest was incubated at 37° C. for approximately 16 hours. The digest was subjected to 0.8% agarose gel electrophoresis in TAE buffer and blotted onto hybond N+ (GE Healthcare Life Sciences, Manchester, NH, USA) using a TURBOBLOTTER® for approximately 1 hour according to the manufacturer's recommendations. The membrane was hybridized with a 481 bp digoxigenin-labeled Aspergillus niger steroid dehydrogenase probe, which was synthesized by incorporation of digoxigenin-11-dUTP by PCR using primers IH1252-ste-proF (sense) and IH1253-ste-500R (antisense) shown below. SEQ ID NO: 47: Primer IH1252-ste-proF: 5'-ATACTCTCCGTCAGCATCCTGCCAG-3' SEQ ID NO: 48: Primer IH1253-ste-500R: 5'-CTGCTCCTTCGATCCATAAGGCAAC-3'

[0193] Amplification reactions (50 μl) consisted of 200 μM PCR DIG Labeling Mix (Roche Applied Science, Palo Alto, CA, USA), 0.5 μM primers with KOD-Plus (TOYOBO) using plhar473 in a final volume of 50 μl. Amplification reactions were incubated in a Bio-Rad® C1000 Touch™ Thermal Cycler, which was programmed as follows: 1 cycle at 94°C for 2 min; 30 cycles each of 94°C for 15 s, 55°C for 30 s, and 68°C for 30 s, with a hold at 4°C. PCR products were purified by 0.8% agarose gel electrophoresis with TAE buffer, where a 0.5 kb fragment was excised from the gel and then extracted with a QIAQUICK® Gel Extraction Kit. The denatured probe was added directly to DIG Easy Hyb buffer, and hybridization was carried out at 42°C overnight. After post-hybridization washing (2 times with 2x SSC, room temperature, 5 min, and 2 times with 0.1x SSC, 68°C, 15 min, respectively), chemiluminescence detection was performed using the DIG detection system and CPD-Star (Roche) according to the manufacturer's protocol. DIG-labeled DNA molecular weight marker II (Roche) was used as a standard marker. The 474P2-1 and 474P2-5 strains (hybridizing bands changed from 5118 bp to 7612 bp), which resulted in accurate integration at the steroid dehydrogenase locus, were selected for further experiments.

[0194] Example 27: Expression of Aa lysozyme in 474P2-1 and 474P2-5 Chromosomal insertion of the Aa lysozyme gene with the amdS selection marker into A. niger 474P2-1 and 474P2-5 (pJaL1470 as described in WO2015144936A1) was performed as described in WO2012 / 160093. The Aa lysozyme expression plasmid was targeted by flp recombinase to four pre-specified loci: mannosyltransferase (alg2), glucokinase (gukA), acid-stable amylase (asaA) and multicopper oxidase (mcoH).

[0195] Chromosomal insertion of the Aa lysozyme gene into the reference steroid dehydrogenase-wild type A. niger C5553 was also performed. Fully grown strains were purified and subjected to Southern blotting analysis to confirm whether the Aa lysozyme gene was correctly introduced into the mcoH, gukA, asaA and alg2 loci. Selected transformants were analyzed using the following primer set to generate a non-radioactive probe:

[0196] For the promoter region: SEQ ID NO: 49: HTJP-324 AAGGGATGCAAGACCAAACC SEQ ID NO: 50: HTJP-325 TGAAGAATTTGTGTTGTCTGAG

[0197] Genomic DNA extracted from the selected transformants was digested with SpeI and then probed for promoter regions. Correct gene transfer events showed hybridization signals of 6.7 kb (alg2), 2.9 kb (mcoH), 6.7 kb (gukA) and 2.7 kb (asaA) sizes by digestion with SpeI and MluI, and were probed as above.

[0198] Among the strains assuming correct integration events of four copies of genes at the mcoH, gukA, asaA and alg2 loci, one strain with lysozyme from each host (1470-474P2-1, 1470-474P2-5, 1470-C5553-13) was selected.

[0199] Example 28: Effect of steroid dehydrogenase gene disruption on enzyme production One strain from 474P2-1, 474P2-5 and C5553 was fermented in laboratory scale tanks and their enzyme activities (LSU(F) / ml activity) were measured according to the materials and methods described in Example 7; the results are shown in the table below. The steroid dehydrogenase disruptant strain showed about 1.1-fold higher lysozyme (LSU(F) / ml) activity than the reference steroid dehydrogenase-wild type strain in glass fermenters (Table 3).

[0200] [Table 4]

[0201] Example (Aspergillus oryzae) microbial strains The AT3091 strain expresses the Citrobacter braakii phytase described in SEQ ID NO: 4 of WO2006037328. The strain has eight gene copies of the Citrobacter braakii phytase inserted as tandem inverted repeats at four specific loci on four separate chromosomes using the FLP integration system described in WO2012160093. The host used to generate the AT3091 strain is derived from JaL1903 described in Example 4 of WO2018167153.

[0202] Laboratory-scale tank culture of Aspergillus oryzae strains. The fermentation was carried out as fed-batch fermentation (H. Pedersen 2000, Appl Microbiol Biotechnol, 53:272-277), in which the selected strains were pre-cultured in liquid medium and then the grown mycelium was transferred to tanks for further cultivation and enzyme production. The cultivation was carried out at 34°C for 8 days. Ammonia was used to control the pH. The pH was kept at 6 during the batch phase and at pH 5.4 in the fed-batch phase. Nutrients were added with maltose syrup. The culture broth was used for enzyme assays.

[0203] Phytase activity measurements were performed as described in Example 4 of WO2006037328.

[0204] Example 29 - Construction and testing of phytase-expressing strains with truncated steroid dehydrogenase genes To generate a truncated steroid dehydrogenase of A. oryzae steroid dehydrogenase (SEQ ID NO: 9) encoded by SEQ ID NO: 7 (genomic) and SEQ ID NO: 8 (cDNA) to resemble the T. reesei steroid dehydrogenase mutant (NJOC586), a stop codon was introduced at amino acid position Y234 by mutating the codon TAT to TAG.

[0205] To introduce a stop codon, oligonucleotide-mediated CRISPR gene editing was performed as described in Noedvig et al. Fungal Genetics and Biology 115 (2018) 78-89, with the modification of replacing Cas9 with Mad7 provided by Incripta.

[0206] The oligo oAT3303 used for the mutation is in antisense orientation and has the following sequence (SEQ ID NO:51): [ka]

[0207] The two underlined and bolded nucleotides mutated at the PAM site changed the codon corresponding to Y234 to a stop codon to prevent further cleavage by the Mad7 complex.

[0208] CRISPR-Mad7 plasmid pAT3631 (Figure 13, SEQ ID NO:52) was constructed by modification of pAT1153 (WO19046703, Example 25) in such a way that 1) the cas9 gene was replaced with the mad7 gene, 2) the pyrG marker gene was replaced with the bar gene (conferring resistance to bialaphos) (Thompson et al. 1987, EMBO J 6:2519-2523), and 3) the wA protospacer was replaced with the protospacer TCTCTCAAGAAGTACACCCTT (SEQ ID NO:53), which targets the corresponding chromosomal sequence and has the PAM site TTTC immediately upstream of the target sequence.

[0209] Aspergillus transformation of AT3091 was performed according to Christensen et al., 1988, Biotechnology 6:1419-1422. Briefly, A. oryzae mycelia were grown in rich nutrient broth. The mycelia were separated from the broth by filtration. The enzyme preparation Glucanex® (Novozymes A / S) was diluted with 1.2 M MgSO4 buffered to pH 5.0 with sodium phosphate. 4 The suspension was incubated at 37°C for 60 min with stirring. The protoplasts were filtered through Miracloth® (Calbiochem Inc.) to remove mycelial debris. The protoplasts were collected and washed twice with STC. The protoplasts were then resuspended in 200-1000 μl of STC.

[0210] For transformation of AT3091, 1 μg of plasmid pAT3631 and 100 picomoles of repair oligo oAT3303 were added to 100 μl of protoplast suspension, followed by 200 μl of PEG buffer. The mixture was incubated at room temperature for 20 min. Protoplasts were collected, washed twice with 1.2 M sorbitol, and resuspended in 200 μl of 1.2 M sorbitol. Transformants containing the bar gene were selected for their ability to confer resistance to bialaphos when selecting for transformants on minimal medium agar plates (Cove, 1966, Biochem. Biophys. Acta. 113:51-56) containing 1.0 M sucrose as carbon source and 10 mM urea as nitrogen source and 100 mg / l bialaphos. After 5-7 days of growth at 37°C, stable transformants appeared as vigorously growing and sporulating colonies. Transformants were purified once through conidiophores on non-selective plates (i.e., without bialaphos), where the CRISPR-mad7 plasmid was lost.

[0211] To verify the predicted mutations, the following primers were used on selected transformants: oAT3163: CTAGCAGTCTCAATCGC (SEQ ID NO: 54) oAT3164: TTGACCGTGACAAAGAC (SEQ ID NO: 55) PCR was performed using the primers and the resulting 404 bp PCR product was sequenced using the primers used for PCR. One transformant, AT3944, with an introduced stop codon, was selected in laboratory tank fermentation.

[0212] Fermentation of AT3091 and AT3944 and phytase activity were performed as described below. From 117.4 hours to the end of fermentation, the phytase activity of AT3944 was 1.4%-6.9% higher (ending at about 3% higher after 182.7 hours, Figure 14). The results show that inactivation of putative native steroid dehydrogenases has a positive effect on phytase expression in Aspergillus oryzae.

[0213] The invention described and claimed herein should not be limited in scope by the specific embodiments disclosed herein, as these embodiments are intended as illustrations of some aspects of the invention. Any equivalent embodiments are intended to fall within the scope of the invention. Of course, various modifications of the invention, in addition to those shown and described herein, will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to be included within the scope of the appended claims. In case of conflict, the present disclosure, including definitions, will control.

Claims

1. 1. A mutant filamentous fungal host cell producing a secreted polypeptide of interest, said mutant filamentous fungal host cell comprising a polynucleotide construct encoding said secreted polypeptide of interest, wherein a putative native steroid dehydrogenase is modified, truncated, partially or completely inactivated, present at reduced levels or eliminated compared to a non-mutated parent cell, and wherein said putative native steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; and wherein said putative native steroid dehydrogenase comprises or consists of an amino acid sequence at least 90% identical to the mature amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and / or SEQ ID NO:26, A mutant filamentous fungal host cell, wherein the genus of the host cell is Trichoderma or Aspergillus.

2. Aspergillus aculeatus, Aspergillus aculetinus, Aspergillus awamori, Aspergillus brasiliensis, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus ryukyuensis 2. The host cell of claim 1, which is selected from the group consisting of Aspergillus luchuensis, Aspergillus nidulans, Aspergillus niger and Aspergillus oryzae.

3. 2. The host cell of claim 1, which is a Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei or Trichoderma viride cell.

4. The host cell according to any one of claims 1 to 3, wherein the secreted polypeptide of interest is native or heterologous.

5. 5. The host cell according to any one of claims 1 to 4, wherein the putative native steroid dehydrogenase is encoded by a gene comprising or consisting of a nucleotide sequence that is at least 90% identical to the genomic DNA sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and / or SEQ ID NO:

10.

6. 6. The host cell according to any one of claims 1 to 5, wherein the putative native steroid dehydrogenase is encoded by a gene comprising or consisting of a nucleotide sequence that is at least 90% identical to the cDNA sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and / or SEQ ID NO:

11.

7. 7. The host cell according to any one of claims 1 to 6, wherein the putative native steroid dehydrogenase is modified, truncated, partially or completely inactivated, present at reduced levels compared to a non-mutated parent cell, or eliminated by a nonsense or frameshift mutation in the encoding gene, by partial or complete deletion of the encoding gene, or by silencing of the encoding gene.

8. A method for producing a mutant filamentous fungal host cell having an improved yield of a secreted polypeptide of interest compared to a non-mutated parent host cell, comprising the steps of: a) transforming a filamentous fungal host cell with a polynucleotide construct encoding the secreted polypeptide of interest; b) mutating said host cell to modify, truncate, partially or completely inactivate, reduce the level of or eliminate a putative naturally occurring steroid dehydrogenase, wherein said putative naturally occurring steroid dehydrogenase comprises at least one conserved amino acid motif selected from YGAR and / or VPHS[W / Y]F and / or QC[A / V / S]RRL and / or LKKYTLP and / or CPHYT; and wherein said putative naturally occurring steroid dehydrogenase comprises or consists of an amino acid sequence at least 90% identical to the mature amino acid sequence set forth in SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9 and / or SEQ ID NO:26, The method, wherein the genus of the host cell is Trichoderma or Aspergillus.

9. The filamentous fungal host cell is selected from the group consisting of Aspergillus aculeatus, Aspergillus aculetinus, Aspergillus awamori, Aspergillus brasiliensis, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus ryukyuensis, Aspergillus spp., Aspergillus spp., Aspergillus spp., Aspergillus spp., Aspergillus spp., Aspergillus spp., Aspergillus spp., Aspergillus spp. The method according to claim 8, wherein the species of the fungus is Aspergillus luchuensis, Aspergillus nidulans, Aspergillus niger or Aspergillus oryzae.

10. 9. The method of claim 8, wherein the filamentous fungal host cell is a Trichoderma harzianum, Trichoderma koningii, Trichoderma longibrachiatum, Trichoderma reesei, or Trichoderma viride cell.

11. The method of any one of claims 8 to 10, wherein the secreted polypeptide of interest is an enzyme.

12. 12. The method according to any one of claims 8 to 11, wherein the putative native steroid dehydrogenase is encoded by a gene comprising or consisting of a nucleotide sequence that is at least 90% identical to the genomic DNA sequence shown in SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7 and / or SEQ ID NO:

10.

13. 13. The method according to any one of claims 8 to 12, wherein the putative native steroid dehydrogenase is encoded by a gene comprising or consisting of a nucleotide sequence at least 90% identical to the cDNA sequence shown in SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8 and / or SEQ ID NO:

11.

14. 14. The method of any one of claims 8 to 13, wherein the putative native steroid dehydrogenase is modified, truncated, partially or completely inactivated, present at reduced levels compared to a non-mutated parent cell, or eliminated by a nonsense or frameshift mutation in the encoding gene, by partial or complete deletion of the encoding gene, or by silencing of the encoding gene.

15. 10. A method for producing a secreted polypeptide of interest, comprising culturing a mutant filamentous fungal host cell according to any one of claims 1 to 7 under conditions practical for said production of said secreted polypeptide.

Images